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Abstract 
Large-Scale Integration of Microarray Data: Investigating the Pathologies of Cancer and 
Infectious Diseases 
Noor Dawany 
Aydin Tozeren, PhD 
 
 
 
DNA microarray data provide a high-throughput technique for the genome-wide profiling of 
genes at the transcript level.  With large amounts of microarray data deposited on various types 
and aspects of malignancies, microarray technology has revolutionized the study of cancer.  Such 
experiments aid in the discovery of novel biomarkers and provide insight into disease diagnosis, 
prognosis and response to treatment.  Nonetheless, microarray data contains non-biological 
obscuring variations and systemic biases, which can distort the extraction of true aberrations in 
gene expression.  Moreover, the number of samples generated by a single experiment is typically 
less than is statistically required to support the large number of genes studied.  As a result, 
biomarker gene lists produced from independent datasets show little overlap.  Therefore, to 
understand the pathophysiology of cancers and the influence they exert on the cellular processes 
they override, methods for combining data from different sources are necessary. 
 
Meta-analysis techniques have been utilized to address this issue by conducting an individual 
statistical analysis on each of the acquired datasets, then incorporating the results to generate a 
final gene list based on aggregated p-values or ranks.  However, much of the publicly accessible 
cancer microarray datasets are unbalanced or asymmetric and therefore lack data from healthy 
samples.  Consequently, critical and considerable amounts of data are overlooked.  An integrative 
approach that combines data prior to analysis can incorporate asymmetric data.  For this reason, a 
merge approach to the previously validated technique, the significance analysis of microarrays, is 
proposed.  The merged SAM technique reproduced the known-cancer literature with higher 
coverage than meta-analysis in the five independent cancer tissues considered.  The same 
xiii 
 
methodology was extended to a database of approximately 6000 healthy and cancer samples 
arising from thirteen tissues.  The integrative approach has allowed for the identification of key 
genes common to the invasive paths of multiple cancers and can aid in drug discovery.  
Moreover, this integrative microarray approach was applied to viral data from HIV-1, hepatitis C 
and influenza to investigate the effect of these infections on iron-binding proteins.  Iron is crucial 
for proteins involved in metabolism, DNA synthesis and immunity, accentuating such proteins as 
direct or indirect viral targets. 
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Chapter 1: Introduction 
 
1.1 Motivation: 
This research is dedicated to the investigation of complex diseases through gene expression 
analysis.  A large effort has already been directed towards the study of cancer, however many 
results from these various studies are inconsistent.   The goal of this research is to provide a 
robust statistical approach that can help integrate different datasets to provide a generalized 
overview of the genetic aberrances that can be introduced during the course of carcinogenesis.  
The proposed methodology is also designed to take advantage of the current distribution of gene 
expression data, which in many cases is more inclined towards providing data on diseases and 
anomalous states as opposed to healthy control samples.  The initial application of this approach 
was directed towards the study of cancer, a multifaceted disease comprising over 200 different 
malignancies, in order to identify common genetic alterations that could serve as effective drug 
targets.  However, the scope of its application is unlimited and has been extended to understand 
the repercussions induced by persistent viruses such as HIV and hepatitis C as opposed to 
cytopathic viruses whose etiological agents are cleared quickly by the immune system. 
 
1.2 Transcription, Translation and Control of Gene Expression: 
Biological systems, whether at the level of a single cell, a multicellular tissue or a multi-tissue 
organism are complex entities.  From an engineering perspective, these entities consist of several 
physiochemical and mechanical processes, which are governed by genes and proteins [1].  The 
human genome is coded into double-stranded DNA.  A substantial fraction of the DNA can be 
transcribed to allow for the expression of the coded information in directing the synthesis of RNA 
and eventually protein molecules.  The transcription process alone is sufficient for producing the 
functional RNA molecules (Figure 1) including messenger RNA (mRNA), transfer RNA (tRNA) 
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and ribosomal RNA (rRNA) [2].  The genetic coding region, however, is not necessarily 
continuous; instead the exon coding regions are interspersed with introns or non-coding regions.  
Introns are spliced out following transcription and prior to leaving the nucleus to the cytoplasm as 
part of the post-transcriptional modifications that mRNA undergoes before being translated [3].  
While nucleic acids store and transmit the genetic information of the cell, the information itself is 
expressed in the form of proteins, therefore the protein-coding information from mRNA is 
translated into amino acid units that are connected to each other using peptide bonds to form 
polypeptides (Figure 1).  The formation of the final protein depends on the number of polypeptide 
chains it contains, as well as the final three-dimensional structure it assumes which is determined 
by internal and external interactions with the protein’s environment.  The multiplicity of protein 
functions within cells ranges from reaction catalysis, transport of molecules and ions to immune 
response [2]. 
 
 
Figure 1 - Transcription and Translation (Adapted from [4]) 
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In humans and multicellular organisms that possess more than one cell type, gene expression has 
to be controlled such that cells from distinct lineages develop differently and remain to be 
different.  While the DNA code in the cells of an organism’s pancreas and kidney are identical, 
they express different proteins at different levels.  Therefore, during development and 
differentiation, cells have to control the expression of different sets of genes by switching them 
on and off as needed [3].  As transcription and translation are localized within different areas in 
the cell, gene expression can be accordingly regulated at more than one stage and location within 
cells [3, 5].  The primary mode however occurs in the nucleus as RNA polymerase interacts with 
the DNA promoter to initiate transcription.  This binding can be sufficient for producing a few 
RNA molecules; however, the binding of transcription factors to enhancer sequences is essential 
for determining whether a gene will be transcribed.  These transcription factors therefore help in 
regulating the time during which a gene is transcribed.  This ensures that transcription occurs at 
the right developmental stage for example, and the right tissue location in which a gene is 
expressed.  Nonetheless, additional regulatory instances can occur that could alter the way by 
which the primary mRNA transcript is processed or control the level of translation in the 
cytoplasm [3].  Hence, apart from their individual roles, the interactions between DNA, RNA and 
proteins are also important.  DNA-protein interactions control gene expression, transcription, 
recombination, replication, packaging and repair.  Similarly, since RNA is involved in various 
biological functions within the cell, RNA-protein complexes are also essential for these 
processes, including post-transcriptional regulation of gene expression and protein synthesis 
during translation [6].   
 
Since the entire cell’s genetic information is encoded within its DNA, the DNA must be faithfully 
replicated during every division cycle a cell undergoes.  This ensures that the encoded genetic 
information is retained in the progeny cells.  While DNA molecules possess a very stable 
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structure and have a longer half-life than RNA molecules, changes in the DNA sequence still 
occur.  Alterations in DNA replication must be repaired and, in general, the location where the 
error exists is excised by DNA repair enzymes to readjust the base sequence.  Since DNA is 
double stranded, the enzymes are required to identify which of the two strands is in fact damaged 
[3].  Despite employing repair mechanisms to control and fix DNA damage, cells can still 
undergo mutations that result in permanent changes to their genome.  Genomic damage can arise 
from internal and external processes.  Internally, damage can occur from errors during DNA 
replication, the chemical instability of some DNA bases and from free radicals produced during 
metabolism.  On the other hand, external causes of DNA damage can be produced from 
interactions with ionizing radiation, ultraviolet radiation and certain chemicals, which can result 
in a cascade of mutations, especially if the damage is directed towards genes whose function is to 
ensure the accuracy of DNA replication [7].  Genetic variations can occur in different forms, 
ranging from deletions, insertions or single nucleotide polymorphisms, to large chromosomal 
anomalies like copy number variation, where whole sections of homologous sequences are gained 
or lost.  Such changes can affect gene expression and alter gene dosage, leading to diseases, 
disorders or increased predisposition to genetic mutations [8]. 
 
1.3 Cancer Overview 
Normal cells progressively transform into malignancies through the sequential acquisition of 
mutations that occur due to damage to the genome (Figure 2).  The main targets for the 
progression of normal cells into malignant ones are genes involved in normal homeostatic 
mechanisms.  These genes are therefore mainly involved in cell growth and death.  Namely these 
targets are the oncogenes, which are activated by mutations and hence stimulate proliferation, or 
tumor suppressor genes, which typically code for proteins that behave as checkpoints during cell 
proliferation or death and are therefore inactivated by mutations [7].  Oncogene mutations can 
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occur through gene amplifications, chromosomal translocations, or mutations in the regulatory 
machinery of the gene.  Examples of oncogenes include Jun oncogene, and myelocytomatosis 
viral oncogene homolog (MYC).  Tumor suppressor genes, like tumor protein p53 and breast 
cancer 1 and 2 (BRCA1/2) are targeted in the opposite manner with mutations resulting in 
shortened proteins due to deletions or insertions, missense mutations, or epigenetic silencing 
factors [9], like hypermethylation [10].  In some cases, inactivating mutations occur in genes that 
are involved in maintaining genomic integrity, thus facilitating the acquisition of additional 
mutations [7].  These stability genes could be involved in subtle DNA repair, including mismatch 
repair (MMR) and base-excision repair (BER) or can control processes involving larger 
chromosomal regions like segregation and recombination.  Therefore, a single mutation is not 
sufficient to infer cancerous transformation.  Instead, several mutations have to be acquired and 
while all genes can be affected by mutations in stability genes, only mutations in oncogene and 
tumor suppressor gene regulation affect the net proliferation of the cell [9]. 
 
 
Figure 2 - Carcinogenesis: Transformation of normal cells into cancer (Adapted from [11]) 
 
Cancer is often preceded by chronic inflammation, although the role of inflammation in the 
malignant transformation is not fully understood.  Examples include lung cancer following 
inflammation due to smoking and colon cancers following chronic inflammatory bowel disease.  
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As a result, several factors can induce cancer and these can be broadly categorized into events or 
agents.  Events include environmental factors such as diet, occupation and chemical agents like 
carcinogens in tobacco.  Meanwhile, several infectious viral agents can also promote cancer, 
including Helicobacter pylori causing gastric cancer, hepatitis B and C causing hepatocellular 
carcinoma and human papillomavirus leading to cervical cancer.  While the specific genes 
involved might differ, the general mechanism of such infections involves triggering an 
inflammatory response through cytokines, chemokines and free radicals.  The inflammatory 
response leads to the release of more free radicals which can contribute to the genetic mutations 
leading to the malignant transformation [12]. 
 
Regardless of cause or origin, once a cell has acquired and sustained a series of irreversible 
genetic alterations, a cancer develops through stochastic proliferation and differentiation [13].  
Upon the completion of this transformation, a cancer cell must achieve two requirements to allow 
for its continual survival; it must overcome replicative senescence and obtain sufficient amounts 
of nutrients and oxygen supplies to support its high prolific activities by promoting angiogenesis 
[7].  Some cancers then metastasize beyond the site of their initial growth by entering the 
lymphatic system or the blood stream and localizing in a new tissue [14].  Because of the large 
heterogeneity of the different malignancies and the complex interplay between the various 
affected genes and pathways, the proliferation, progression and spread of cancer are all highly 
dependent on the alteration initially experienced by the primary cell and the resultant changes the 
cancer can impose on its surroundings. 
 
1.4 Viral Infections and Hijacking Cellular Functions 
There are two strategies that viruses generally employ for their survival.  The first is a “hit and 
run” approach resulting in a quick infection, viral replication, cytolysis and transmission to a new 
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host.  Such viruses are usually highly infective and easily transmissible like influenza and 
measles.  However, other viruses are persistent, achieving long-term residence within the host.  
Either way, the virus must compete with the host cell for control of the cell’s machinery, and it 
often dominates various components of the cellular mechanisms, imposing changes to the gene 
expression and pathway regulation through viral-host protein crosstalk [15]. 
 
1.4.1 Human Immunodeficiency Virus 
The Human Immunodeficiency Virus (HIV) is the causative agent of the Acquired 
Immunodeficiency Syndrome (AIDS), perhaps the most serious viral infection to affect humans.  
HIV accounts for approximately 42 million cases worldwide, and the fatality rate is almost 100% 
[16].  There are two known types of HIV: HIV-1 and HIV-2, however the two types are not 
closely related to one another [17].  HIV-2 has a slower disease progression and limited impact 
on the survival of the majority of the infected adults compared to HIV-1 [18].  As a result, HIV-2 
is confined to specific countries and has reduced pathogenecity.  Moreover, there is better 
immune control of HIV-2 and a degree of CD4-independence.  Most infections are caused by 
HIV-1 viruses [19], therefore from hereafter, the use of HIV will refer solely to HIV-1 infections. 
 
The genome of HIV (Figure 3) is approximately 10 kilobases long and encodes 16 distinct 
proteins.  The structural proteins are encoded into three HIV genes: group specific gene (Gag), 
polymerase (Pol), and envelope (Env).  The remainder of the proteome consists of two regulatory 
proteins and four accessory proteins.  The regulatory proteins: transcriptional transactivator (Tat) 
and regulator of virion gene expression (Rev) as well as the accessory protein negative effector 
(Nef) are expressed early in the viral cycle.  Tat and Nef are necessary for inducing high levels of 
viral replication, while Rev regulates the gene expression transition from the early to late stages 
[20].  As HIV infects cells of the immune system, dendritic cells are believed to be among the 
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first cells that encounter the virus.  Therefore, they mediate the transmission of HIV to CD+ T 
cells in the lymphoid tissue [21].  Viral entry into the immune system cells depends on the 
presence of specific chemokines receptors.  HIV R5 strain binds to the CC-chemokine receptor 5 
(CCR5) which is expressed on the surface of macrophages, dendritic cells and T cells.  The X4 
strain however can only infect T cells as it depends on CXC chemokines 4.  Once inside, the virus 
is uncoated, its RNA is reverse transcribed and the resulting DNA is integrated into the cell’s 
genome with a preference for active genes.  Upon integration, the T cells become permissive 
allowing for the progression of the HIV infection.  Tat controls the production of full-length viral 
transcripts.  The mature HIV particles are then assembled and surrounded by the viral envelope in 
which the glycoproteins Gp120 and Gp41 are embedded, which are essential for viral binding to 
new cells  [20]. 
 
 
Figure 3 - Human Immunodeficiency Virus: Structure of HIV 
 
What adds to HIV’s chronicity is its ability to evade the host’s immune system.  Viruses can 
achieve that either by hiding in the microglial cells of the central nervous system since cell-
mediated responses are naturally reduced there, or otherwise they enter a state of proviral latency 
in resting T cells.  In addition, Nef decrease the expression of major histocompatibility complex 
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(MHC) class I molecules on the cell surface.  Finally, once an infected cells has produced enough 
copies of the virus, HIV promotes apoptosis through the FAS and TNF death-inducing signaling 
pathways allowing for the virus to be released in order to infect new cells [20].  Consequently, 
following infection, there is a gradual loss of T cells resulting in a progressive immune deficiency 
that ultimately leads to opportunistic infections and death [22].   
 
1.4.2 Hepatitis C 
The hepatitis C virus is characterized by its high chronicity and it presents an international public 
health problem.  It is transmitted primarily through the blood and is believed to infect 
approximately 3% of the world population.   Hepatitis C infects the host’s liver and can lead to 
acute hepatitis (20% of cases) or chronic hepatitis (up to 80% of cases).  It can also lead to liver 
cirrhosis and has been associated with hepatocellular carcinoma [23-24].  The development of 
chronic hepatitis C depends on several factors including the viral genotype, the mode of viral 
acquisition and the immune response of the host [24]. 
 
Structurally, the virus has a positive sense, single-stranded RNA genome that is contained within 
a nucleocapsid [23-24].  The RNA and nucleocapsid are then packaged into an envelope that is 
derived from the host cell membrane upon viral release from the cell, in which viral-encoded 
glycoproteins are embedded (Figure 4).  The RNA open reading frame encodes a polyprotein that 
is about 3300 amino acids long, which is cleaved inside the host cell to produce ten different 
polypeptides: the core peptide, two envelope peptides, six non-structural proteins in addition to a 
small hydrophobic protein [24-25].  The non-structural proteins comprise the RNA replicase 
complex of the virus needed for replication, while the core protein binds viral RNA to regulate its 
translation [25]. 
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Figure 4 - Hepatitic C Virus: Structure of Hepatitis C 
 
Aside from the typical role of the core protein, it possesses a wide array of functions as it 
interacts with several host proteins.  First, Core has been shown to bind heterogeneous nuclear 
ribonuclearprotein K (hnRNP K), which in turn can recruit a range of molecules involved in 
signal transduction and transcriptional regulation.  hnRNP K can also bind to DNA, RNA and 
transcriptional repressors and activators, in addition to acting as a shuttle between the nucleus and 
cytoplasm, implicating that it might be involved in RNA transport.  Core also interacts with 
Lymphotoxin β receptor (LT-βR), a member of the tumor necrosis factor receptor (TNF-R) 
superfamily, expressed on the surface of most cell types.  In addition, Core can bind to TNF-R1 
which mediates the tumor necrosis factor induction.  More specifically, the viral protein 
associates with the death domain contained within TNF-R1 that triggers the activation of 
consequent cell signaling pathways that control apoptosis.  Studies have also reported Core’s 
interaction with an RNA helicase belonging to the DEAD box protein family, which are involved 
in several cellular activities such as mRNA splicing, RNA transport, ribosome assembly and 
translation, as well as controlling growth and differentiation [26].  As a result, the Core protein 
affects cell signaling, lipid metabolism, apoptosis, and carcinogenesis [25-26], although it is 
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unclear if these events are direct results of the viral infection or outcomes of protein over-
expression within the cells [25]. 
 
Hepatitis C is also capable of avoiding the host’s immune system by perturbing the host’s ability 
to detect and destroy infected cells [26].  Over the course of an infection, Hepatitis C, like HIV, 
results in escape mutations.   The host’s immune response can be evaded by substituting the 
epitopes of nearby T cells by decreasing binding of the MHC and impairing antigen processing 
[27].  The virus can then persist and additional complications can arise that are associated with 
the autoimmune state of the host.  These include the development of other syndromes like non-
Hodgkin’s lymphoma or coinfections with other viruses such as other hepatitis strains or HIV, 
thus further interfering with the cellular machinery and compromising the host’s defense 
mechanisms [28]. 
 
1.4.3 Influenza A 
The threat of human influenza epidemics is a recurrent issue which infrequently progresses into 
major worldwide pandemic as antigenically novel viruses are introduced to immunologically 
naïve human populations [29].  Influenza viruses have a segmented, negative sense RNA genome 
that is encapsidated by a viral nucleoprotein.  Influenza is categorized into three types; A, B and 
C, based on the serological responses to their internal proteins [30-31].  However, influenza A has 
a greater impact on the human population as it is more common than type B [29], and generally 
causing the most serious respiratory illness compared to both types B [31] and C [30].  While the 
natural hosts for type A are aquatic birds, the viruses can infect a large variety of avian and 
mammalian species [29-31]. 
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Influenza A viruses are composed of eight RNA segments that code for eleven viral proteins: two 
surface antigens, a nucleoprotein, two matrix proteins, three RNA polymerase proteins, and three 
non-structural proteins (Figure 5) including PB1-F2 which plays a role in apoptosis [32].   These 
A-type viruses encompass a large variety of antigenically distinct subtypes based on the 
serological reactivities to their surface antigens, haemagglutinin (HA) and neuraminidase (NA) 
[30-31], for a total of 16 HA and 9 NA subtypes [33].  The HA glycoprotein is necessary for 
attaching to, and facilitating the entry and fusion into, the host cell. Meanwhile, NA is needed for 
breaking down cellular sialic acid to allow the virus to exit the host cell [34]. 
 
 
Figure 5 - Influenza A Virus: Structure of Influenza A 
 
Upon binding to the host cell, the influenza virus activates proteins from the protein kinase C 
superfamily, which are linked downstream to several signaling pathways  [35].  Once inside, like 
other viruses, influenza A exploits the host’s cellular proteins and pathways to promote its own 
replication.  Upon cellular entry, the viral core is disassembled and the genomic 
ribonucleoprotein (RNP) complexes are released into the cytoplasm and transported into the 
nucleus where the viral genome is transcribed.  Most of the host factors therefore aid the virus by 
facilitating its replication [36].  Moreover, influenza A viruses induce the expression of several 
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cytokines and chemokines affecting their signaling cascades, including interferons α and β, as 
well as several interleukins.  In addition three members of the mitogen-activated protein kinase 
(MAPK) family: extracellular-signal-regulated kinase, JUN N-terminal kinase, and p38, are 
believed to be activated due to influenza infections.  MAPK signaling cascades are generally 
involved in several important cellular responses including cell activation, proliferation and 
differentiation, as well as immune response [35]. 
 
In humans, the influenza virus causes an infection that can vary in severity from asymptotic to a 
serious systemic illness.  While it is unlikely that the virus replicates to a great extent outside of 
the respiratory tract, viral genes have been detected in peripheral blood mononuclear cells but 
without evidence of viral replication.  In addition the viraemia is believed to occur as a result of 
respiratory complications enabling viral entry into the blood [31].  Therefore, the complex 
interactions that occur between viral and host proteins are essential for the virulence and the 
spread of the infection [30, 37]. 
 
In summary, while the cell machinery has been designed to help maintain a homeostatic 
environment ensuring healthy growth and proliferation, external events and infectious agents can 
interfere with these control mechanisms.  Perturbations are introduced directly as mutations 
occur, or indirectly as invading pathogens usurp the cellular machinery.  These changes often 
influence several pathways that occur downstream of the affected proteins, resulting in 
disturbances in the cell’s regular function.  As a result, the severity of these induced changes 
depends on the pathways concerned.  Hence, the most deleterious infections and tumors are those 
that are capable of efficiently hijacking cellular machinery and directing nutrient supplies to meet 
their own demands, creating an environment fit for their continued proliferation and growth, and 
effectively avoiding or compromising the host’s immune system. 
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Our understanding of the changes and influences associated with the invasion and/or progression 
of cancers and viral diseases is incomplete.  One of the approaches that can help in identifying 
these perturbations at the transcript level is gene expression microarrays.  A large effort has 
already been applied to the study of cancer [38-48], and similar analyses have been constructed to 
identify viral-induced changes [49-52], although these experiments have not been as extensive as 
those available for cancer.  Nonetheless, such data allows for the identification of important genes 
and biomarkers that could aid in not only understanding the pathogenesis of different diseases, 
but also help in identifying candidate drug targets.  Gene expression microarray analysis is further 
discussed in the next chapter.  
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Chapter 2: Gene Expression Microarrays 
 
2.1 Introduction 
Over the course of the past few years, the genomes of several organisms have been sequenced, 
however deciphering the DNA sequence does not reveal the function of genes, or the changes that 
occur in organisms due to disease, infections or even aging, for example.  Microarrays have 
emerged as a useful tool for the simultaneous analysis of the expression of thousands of genes.  
They can help identify differentially expressed genes between two states which can facilitate the 
discovery of functionally important genes.  In general terms, microarrays are affinity matrices in 
which labeled RNA or DNA is hybridized in solution to DNA molecules attached to the surface 
of the chip [53]. 
 
There are two basic types of DNA microarrays; complimentary DNA (cDNA) and 
oligonucleotide arrays.  In the former, mRNA is obtained from two samples and labeled with 
different fluorescent dyes (Cy3 for reference sample and Cy5 for test sample).  The experiment is 
then conducted as a competitive assay in which the two samples are hybridized to the same 
microarray chip and relative mRNA levels for each gene can be determined from the Cy3/Cy5 
signal; a method that is termed two-color or two-channel microarrays (Figure 6a) [54].  In 
oligonucleotide arrays, such as Affymetrix GeneChip, each gene is represented by at least one set 
of 11-20 probe pairs, where each probe pair consists of 25 base pairs-long perfect match (PM) 
oligonucleotide probe and a mismatch (MM) probe of equal length.  The MM probe matches the 
PM sequence with the exception of 1 base pair in the middle of the probe (13
th
 position) [54-55].  
The purpose of MM probes is to measure non-specific binding [55].  The information across all 
the probe sets is then integrated and a probe set signal is produced.  Oligonucleotide arrays are 
therefore one channel arrays in which only one sample is hybridized per chip (Figure 6b), and the 
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signal intensities from different chips can be analyzed and compared [54].  Single-color 
microarrays therefore require double the amount of chips needed for a two-color microarray 
experiment. 
 
 
Figure 6 - DNA Microarray: Hybridization using a) two-channel and b) single-channel 
microarray platforms 
 
While single-color arrays produce gene expression intensities for every sample used [54], two-
color cDNA chips only provide a relative difference between two biological samples and 
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therefore are not a reliable source for the evaluation of absolute gene expression levels [56].  In 
addition, most cDNA arrays are in-house made by spotting or gridding the sequences onto a glass 
chip [57-59].  Commercially produced Affymetrix chips, on the other hand, use photolithography, 
utilizing ultraviolet light to direct where the oligonucleotide synthesis occurs on a siliconized 
glass surface [58-59].  Comparing data obtained from different samples as well as from different 
labs therefore requires normalization.  As a result of the differences between the two types of 
microarray technologies, different standardization methods exist in each case.  The normalization 
of custom-made cDNA chips is a complex problem in which the standard used is often based on 
the purpose for which the array was produced [58], hence the focus from hereon will be shifted to 
Affymetrix microarray chips. 
 
2.2 Microarray Normalization: 
When examining microarray data, two types of variation exist: informative variation and 
obscuring variation.  Informative or interesting variations result from the conditions behind the 
study such as alterations accompanying a disease state, the effect of a protein or gene knockout, 
changes in environmental conditions (such as nutrients or temperature), introduction of infectious 
agents, mutations, or cellular stresses.  Obscuring variations, on the other hand, can occur during 
the process of carrying out the experiment and can interfere with the interesting biological 
variations that occur between the two conditions.  Obscuring variations can arise during the 
preparation of samples including variations during mRNA extraction, temperature fluctuations or 
reagent quality.  In addition, some variations can occur while manufacturing the arrays such as 
the hybridization efficiency of the probes and probe concentrations.  Finally, other obscuring 
variations arise from the processing of arrays, either during the hybridization of samples 
(differences in the amount of sample applied, buffer concentration and cross-hybridization 
interferences) or after array hybridization (variation in fluorescent intensity, optical 
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measurements and imaging algorithms) [60].  Thus the purpose of normalization prior to analysis 
is to deal with these obscuring variations [61] and unless the arrays are appropriately normalized, 
comparing values from different samples can lead to misleading results [62]. 
 
2.2.1 Robust Multichip Average Algorithm: 
In order to produce gene expression levels that are representative of the hybridized DNA or 
mRNA samples, the probe intensities for each probe set have to be summarized.  The robust 
multichip average (RMA) algorithm utilizes PM intensities only, as opposed to some of the other 
algorithms that use both PM and MM probes.  The rationale behind this exclusion is due to 
reports that have revealed that the typical subtraction of MM values to correct for non-specific 
binding is not necessarily appropriate since the mathematical subtraction does not directly 
correspond to biological subtraction [55].  The pre-processing of Affymetrix microarray data 
includes three main steps: background-adjustment, normalization and final summarization of 
probe expression levels.  Since all arrays are assumed to have a common mean background level, 
the PM intensities are adjusted to remove the background effect thus providing a more accurate 
absolute level of probe expression.  Following background-correction, probe values are 
normalized using quantile normalization [62].  Values are transformed using the empirical 
distribution of each array and the empirical distribution of the averaged sample quantiles [61].  
The purpose of quantile normalization is to make the distribution of probe intensities the same 
across all the arrays [61-62] and has been shown to produce favorable outcomes in terms of 
speed, variance and bias criteria when compared to other normalization algorithms[61].  Finally, 
for each probe on the array the background-corrected, normalized and log2-transformed PM 
intensities are fit into a linear additive model to remove probe-specific affinities.  Median 
polishing is used to protect against outlier probes and to estimate the model parameters, resulting 
in the robustness of RMA [62]. 
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2.2.2 Reference Robust Multichip Average 
Classic microarray normalization and summarization methods including RMA and other multiple 
array-dependent algorithms present a major limitation in that the final model is applied to all the 
test samples used.  In other words, the training samples and the test samples are the same.  This 
dependency restricts the expansion of the model to additional data due to the lack of archived 
parameters that can be applied to an updated database of microarray samples.  As a result, data 
from two studies cannot be directly compared if each has been normalized separately since each 
analysis used different data to define the normalization parameters and estimate the probe effects.  
This requires that the normalization technique be reapplied to the data as a whole to avoid pre-
processing bias, a process that can create several constraints when dealing with large amounts of 
data, including time and memory restrictions.  The reference robust multichip average (refRMA) 
algorithm, however, allows for the construction of a static normalization scheme that can be 
applied to added data on a continual basis [63].  The normalization process is termed static since 
the previously normalized data are not re-normalized with the addition of new data. 
 
In short, a large number of biologically distinct Affymetrix microarrays are used to train the 
RMA model.  Similar steps are applied to the training data as with the classical RMA, namely 
background-adjustment, quantile normalization and median polishing. The training process then 
produces two archived vectors; a probe effect vector compiled from the individual log-scale 
probe affinity effects and a normalization vector compiled based on the transformed PM 
intensities.  The resulting vectors can then be extended to new test data by using the 
predetermined group of arrays to estimate the effects and the average empirical distribution that 
should be used for the added data.  The final step differs, however, in that a full median polish 
summarization cannot be performed so the median is taken across probes from each probe set 
resulting in probe set level summaries [63]. 
20 
 
 
2.2.3 Custom Chip Definition Files 
Microarray data requires the use of chip definition files (CDF) in order to process the raw 
information obtained from the data files.  Affymetrix CDF files encode the physical design of the 
chip.  They also contain the sequence details that can be used to link the oligonucleotide probes 
that are present on the chip to the investigated transcripts [64].  Much attention has been directed 
towards statistical algorithms for normalizing data and detecting differentially expressed genes, 
yet problems related to probe and probe set identity can result in significant errors, especially 
when expression changes are not dramatic.  Affymetrix had initially utilized the complete 
information available during the design stage, but with the immense progress achieved in genome 
sequencing and annotation in the past years, the Affymetrix probe set designs have become 
suboptimal [65].  Therefore, a gap exists in the correspondence between the probes and probe sets 
from the Affymetrix chips with the genes and transcripts [64-65].  Probe set annotation is 
constantly updated by Affymetrix and it has deviated from the original one-to-one 
correspondence between probe set and transcription locus.  Nonetheless, the updates affect the 
qualitative attributes of the probe sets that control the effective matching between probes and 
genome sequences [64].  Analysis of chip definition files has revealed that several of the old 
probe sets do not truly reflect the expression levels of several significant genes in a given tissue 
[65]. 
 
Entrez custom CDF files are part of a collection of custom CDF files created by Dai et al. [65].  
The process includes mapping probe sequences to individual sequences found in UniGene, 
dbSNP, and the genome sequence of the species and then aligning these sequences.  Probes 
matching non-transcribed regions are excluded and only probes that have one perfect match with 
the corresponding genome sequence are retained.  The probes in all probe sets are also required to 
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be aligned in the same direction on the genome.  Finally, each probe set has to contain at least 
three probe pairs [65].  The resulting expression data is representative of an individual gene as 
opposed to the original Affymetrix CDF that produce gene intensities per probes where one gene 
can be represented by more than one probe and one probe can be mapped to multiple genes.  The 
development of custom CDF files has been shown to significantly improve the outcomes of 
differential expression microarray analysis [64-65]. 
 
2.3 Microarray Analysis and Differential Gene Expression 
Microarray technology has proved to be useful as it allows for the simultaneous quantification of 
thousands of genes in a high-throughput and cost-effect manner [66].  In many cases, the 
objective of the microarray data is to identify genes that are differentially expressed between the 
different conditions considered [67].  As a result, a large variety of methods have emerged for the 
analysis of microarray gene expression data.  One of the simplest calculations is computing the 
fold change of a gene [68].  However, this is a statistically inefficient approach due to the 
systemic and biological variations that occur in such experiments.  While some biases can be 
effectively removed through normalization, sample-to-sample variation cannot be accounted for 
in this manner.  Hence, the use of fold change as the sole statistic of significant genes can 
increase the number of false positives (type I error) or false negative (type II error) identified.  It 
is more appropriate to detect significantly altered genes by calculating a statistic based on 
replicate array data, then ranking genes and determining a cutoff value [69].  Statistical methods 
for ranking genes include the student’s t-test [70], analysis of variance (ANOVA; [71]), Mann-
Whitney test [72] or the Bayesian method [73-74]. 
 
The statistical cutoff can then be set, however it has to balance the false positives and the false 
negatives.  In addition, since a microarray chip contains thousands of genes, setting a cutoff of 
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0.05 for an experiment studying 10,000 genes results in 500 genes falsely inferred as significant, 
exaggerating type I error.  Statistical tests therefore have to deal with problems arising from 
multiple hypothesis testing.  One example is the Bonferroni correction were the significance 
cutoff is divided by the number of genes, but such a correction can be too stringent.  Hence, it is 
more practical to control the expected proportion of false positives by controlling the false 
discovery rate (FDR), as is the case with the significance analysis of microarrays (SAM; [75]) test 
[69]. 
 
2.3.1 Significance Analysis of Microarrays 
Similar to the aforementioned tests, SAM determines significantly altered genes by assigning a 
score to each gene that is based on the change of the gene’s expression relative to the standard 
deviation of the repeated measurements for that gene.  This calculation is similar to that of a t-test 
However, a value is added to the standard deviation in the denominator, minimizing the 
coefficient of variation.  Significance is associated with larger scores passing the set cutoff.  The 
FDR is then calculated to determine what percentage of the genes were identified as significant 
by chance.  FDRs are estimated by using random permutations of the gene expression 
measurements and calculating the expected relative difference for a gene from these 
permutations.  SAM’s performance has been shown to be superior to that of other conventional 
microarray analysis methods [75] 
 
Nonetheless, despite the many statistical methods designed to deal with the different issues that 
arise from determining significant genes, discrepancies in the results from similar studies still 
occur [76].  Microarray studies using different datasets can report non-reproducible findings or 
produce results that are not robust even to the slightest data perturbations.  While such problems 
can occur due to multiple reasons including improper analysis or insufficient control of false 
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positives, as previously discussed, the lab-dependency of results is exacerbated by the small 
number of samples utilized in individual studies.  These numbers are generally much smaller than 
what is statistically needed to support the thousands of genes analyzed.  Therefore, one solution 
to increase the statistical power, reliability and generalizability of microarray-based results is to 
combine information from several existing experiments [46]. 
 
2.3.2 Meta-Analysis 
The term meta-analysis is used to describe statistical approaches that combine the results of 
independent but relevant studies.  Meta-analysis techniques have been widely used for clinical 
trials and epidemiological studies [77-82], as well as for microarray analysis [46-48, 83-86].  In 
general, gene lists can be obtained from different studies and compared and a final gene list is 
produced which reflects the results of the multiple studies.  However, it is more preferable to 
obtain and re-analyze gene expression data from each experiment.  The results are then 
aggregated into a final gene list by considering the statistical enrichment of a gene across all 
studies.  There are four main methods for combining information across studies: vote counting, 
combining ranks, combining p-values and combining effect sizes [46].  In vote counting, a gene 
receives a vote each time it appears to be significant in a list.  However, the main difficulty with 
the approach is determining the minimum number of votes required to deem a gene significant.  
This can be further complicated as some genes may not even be analyzed on specific platforms.  
As a result, resampling methods [87-88] are required to estimate the significance of the different 
findings [89].  When combining ranks, the top-ranked genes are obtained from each study and the 
location of the genes within these lists is used to assess their overall significance [46].  
Approaches for aggregating ranks utilize different algorithms including Markov chains [86] and 
Monte Carlo permutations [76].  P-values can also be combined across studies; in the Fisher’s 
sum [47, 90] approach, for example, the logarithms of the different p-values for a gene are 
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accrued across all experiments.  Finally, effect size can be aggregated, where the effect size 
represents a measure of the strength of the relationship between the two gene states considered, to 
obtain significant and meaningful results.  Combining effect sizes is described in the following 
section as part of the inverse-variance methodology [46]. 
 
2.3.2.1 Inverse-Variance 
The inverse-variance model [91] is believed to be the most comprehensive meta-analysis 
approach that can be applied for the comparison of two-class gene expression microarrays [46].  
It has been used in several microarray-based meta-analysis studies [46, 83-84, 92].  For each gene 
in a study, the effect size and the variance associated with it are calculated.  The effect size can be 
computed using an adjusted value of the initial distance parameter used by Cohen [93] based on 
the typical t-test value where the difference between two independent means is standardized by 
dividing the difference by the common within-population standard deviation.  The adjusted value 
was introduced by Hedges and Olkin [94] as a correction factor for the calculation of the unbiased 
estimate of the effect size.  This adjusts the overestimation of the effect size in studies with small 
sample sizes that results from standardizing the mean difference [46, 94].  A weighted-average, 
inversely-proportional to the variance of the study-specific estimates, is then used to combine the 
effect sizes of a gene across the different studies [46]. 
 
The inverse-variance technique possesses several advantages.  First, the method takes into 
account information from all available genes.  In addition, it can combine data from different 
platform technologies including one-color Affymetrix chips and two-color cDNA microarrays.  
Given the differences in the genes included from one platform to another, whether within the 
same technology (i.e. different Affymetrix platforms), or across technologies (i.e. Affymetrix vs. 
cDNA), some genes will be studied more frequently than others.  It is therefore essential that a 
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statistical approach treats both frequently and rarely studied genes equally, and the inverse-
variance addresses this issue by calculating the weighted average of the effect sizes.  Thus, it 
weighs the contribution of a study by its precision, with more weight emphasis given to larger 
sample studies.  And finally the parameters calculated by the inverse-variance; the pooled effect 
size and the standard error, can be biologically interpreted [46]. 
 
2.4 Databases 
Several online databases are now available, providing access for biological information and data.  
Two of the biggest efforts are the National Center for Biological Information (NCBI; 
http://www.ncbi.nlm.nih.gov) and the European Bioinforamtics Institute (EBI; 
http://www.ebi.ac.uk).  These databases include nucleotide sequence and microarray data, protein 
information, gene descriptions, and disease annotations, among others.  Functional annotation 
databases for gene subsets of interest are also important for providing information on the 
connectivity of these genes and the roles they play within the cell.  These databases help 
categorize genes and proteins based on similarities in their characteristics to provide higher order 
functions. 
 
2.4.1 Microarray Databases: 
With the increasing utilization of microarray data and with raw data availability being required by 
the Microarray and Gene Expression Data Society (MGED Society; [95]), microarray databases 
have aided in simplifying the acquisition of publically accessible data.  NCBI’s Gene Expression 
Ominbus (GEO; [96-97]) and EBI’s ArrayExpress Archive [98] are two such repositories.  Both 
databases support the retrieval of microarray data for analysis from a variety of organisms.  They 
contain extensive amounts of data from different experimental settings including disease states 
and stages, genetic interventions and gene-knockouts, time series, and manipulative treatments 
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and drug therapy [96-98].  The availability of multiple microarray datasets is useful for noise 
reduction and adding sensitivity to the results extracted from the data. 
 
2.4.2 Functional Annotation Databases: 
As sequencing projects continue to provide gene catalogs, the functional annotation of these 
genes is essential yet incomplete.  Biological functions within a cell usually cannot be attributed 
to a single gene or molecule but instead to a group of genes or molecules.  The Kyoto 
Encyclopedia of Genes and Genomes (KEGG; [99-101]) is one of the databases that aim to 
combine genomic information with higher order functional information by integrating the 
available literature on cellular processes.  KEGG links gene sets within a network of interacting 
molecules to provide complexes and pathways in which these genes function.  These pathways 
cover a variety of processes such as metabolic pathways, diseases, genetic and environmental 
information processing, and signaling pathways.  Apart from the visual networks of the pathways, 
KEGG also provides information within its sub-databases including the compound database for 
chemical structures, enzyme database for enzymatic nomenclature, and the reaction database 
containing reaction formulas [99-101]. 
 
The continuous accumulation of biological data and information has also produced a need for 
unifying annotation standards.  The Gene Ontology (GO; [102]) Consortium has therefore 
established the structured vocabulary needed to facilitate communication between researchers as 
well as to provide consistent descriptions of gene products.  The main categories described within 
the consortium are molecular function, biological processes and cellular components.  Molecular 
function focuses on the activities at the molecular level rather than discussing the entities 
(molecules or complexes) that are responsible for the actions, or where and when the activity 
occurs.  Biological processes, on the other hand, describe the biological goals that are 
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accomplished by one or more molecular functions.  Finally, the cellular component term refers to 
the subcellular locations of structures and macromolecular complexes.  The main ontologies are 
divided into several subcategories at different hierarchical levels with increasing degrees of 
specificity, resulting in a dynamic, controlled vocabulary for annotating genes and proteins [102-
103]. 
 
Given a set of genes of interest that could be identified from a microarray experiment, the genes 
can be annotated using KEGG pathways and GO categories.  Over-representation of such terms 
using a hypergeometric test can indicate functional enrichment of gene sets.  These significant 
pathways and GO terms can then indicate which activities and processes are affected by the 
perturbation introduced to the system, providing an intelligible account of the cell’s state under 
the specified conditions.  
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Chapter 3: Asymmetric integration of microarray data outperforms meta-analysis 
approach 
 
3.1 Summary 
This chapter focuses on the integrative and meta-analysis approaches used in the analysis of 
microarray data.  Much of the public access cancer microarray data is asymmetric, belonging to 
datasets containing no samples from normal tissue. Asymmetric data cannot be used in standard 
meta-analysis approaches such as the inverse variance method, but are necessary for obtaining 
large sample sizes for statistical power enrichment. Noting that plenty of normal tissue 
microarray samples exist in studies not involving cancer, the viability and accuracy of an 
integrated microarray analysis approach based on significance analysis of microarrays (merged 
SAM) using a collection of data from separate diseased and normal samples was investigated.  
The research focused on five solid cancer types (colon, kidney, liver, lung, and pancreas), where 
available microarray data allowed for the comparison between meta-analysis and integrated 
approaches.  Results from the merged SAM significantly overlapped gene lists from the validated 
inverse-variance method.  In addition, both meta-analysis and merged SAM approaches 
successfully captured the aberrances in the cell cycle that commonly occur in the different cancer 
types.  However, the integrated SAM analysis replicated the known cancer literature (excluding 
microarray studies) with much more accuracy than the meta-analysis.  The merged SAM test is 
therefore a powerful, robust approach for combining data from similar platforms and for 
analyzing asymmetric datasets, including those with only normal or only cancer samples that 
cannot be utilized by meta-analysis methods. The integrated SAM approach can also be used in 
comparing global gene expression between various subtypes of cancer arising from the same 
tissue. 
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3.2 Background 
Microarray studies typically provide intensity levels for thousands of genes.  However, not only 
are the individual datasets usually small in size, but the inferences made from individual studies 
are often inconsistent with similar studies [76].  As thousands of microarray samples have 
accumulated in publicly accessible databases in the last decade [96-98], several statistical 
methods have been developed to allow for the combination and comparison of data from multiple 
sources.  Among the many methodologies that exist that deal with merging different microarray 
datasets, are the permutation tests [47-48], parametric tests and clustering [104], rank-aggregation 
procedures [86, 105], rank products [106], METRADISC [76], and inverse-variance [46, 83-84].  
The utilization of vast amounts of microarray data provided by different groups is considered to 
increase the reliability of results and weaken the effects of lab-specific noise [107].   
 
The meta-analysis procedures cited above combine results from different studies.  Each dataset is 
analyzed separately.  Genes are associated with an effect size or a p-value.  These are then 
combined across all analyses and a top-ranked gene list is generated based on the aggregated 
effect size or p-value [108].  While some meta-analysis methods require the use of raw data [46-
48], others can depend solely on the ranking of genes from various studies [86, 105].  The meta-
analysis is robust in the sense that it allows for comparisons across different platforms and 
analytical techniques (cDNA and oligonucleotide microarrays).  However, the most important 
limitation the meta-analysis poses is that it requires datasets to include both control and test 
samples.  Previous studies showed that aggregating data prior to obtaining results is usually more 
powerful than obtaining separate statistics from each dataset and then integrating the results 
[109].  Therefore, based on the grounds of previous studies that revealed the predictive potential 
of integrated microarray [110-112], this study considers a large-scale merge approach to the 
significance analysis of microarrays (SAM; [75]) test that can utilize asymmetric datasets. 
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To test the performances of the meta-analysis and the merged SAM approach, microarray data 
was compiled from 31 laboratories, resulting in a database containing 339 healthy tissue samples 
and 1,429 cancer samples from five different tissue types using comparable Affymetrix platforms.  
The tumor tissue types considered in this study –colon, kidney, liver, lung, and pancreas – had 
multiple microarray datasets containing both normal and disease samples.  The meta-analysis 
approach has already been employed by a few cancer microarray studies either focusing on a 
single tissue type [47, 84, 113-115] or across different tissues in order to identify gene sets 
associated with common cancer mechanisms [46, 48, 116].  For the purpose of this study, the 
inverse-variance (IV) test was adopted from the work of Ramasamy et al. [46] to compare the 
quality of our results, since it is believed to be the most comprehensive meta-analysis method for 
two-class microarray gene expression analyses.  With this large-scale database, significantly 
altered gene lists were generated for each individual tissue as well as across all five tissue types, 
using both the IV and the merged SAM tests.  The results revealed that the merged SAM analysis, 
when based on large-scale data, not only significantly overlaps the results produced by the IV 
meta-analysis, but also provides gene lists that replicate the known cancer literature at least as 
well as the IV test. 
 
3.3 Materials and Methods 
3.3.1 Microarray dataset selection 
A total of 31 Affymetrix microarray datasets containing 1,768 unique samples from human 
cancer (1,429) and corresponding healthy control tissues (339) were collected from the Gene 
Expression Omnibus (GEO; [96-97] and Array Express [98] online repositories.  Samples were 
selected for five different tissue types: colon, kidney, liver, lung and pancreas, then categorized 
into cancer and control subsets to allow for intra- and inter-tissue comparisons.  The cancer 
samples were not restricted to a single type of malignancy in order to provide a generalized 
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pathogenic approach shared by cancers.  The microarray data were limited to those hybridized on 
the Affymetrix human microarray platforms HG-U133A, HG-U133A 2.0, and the HG-U133 Plus 
2.0 due to the large overlap between the three platforms.  In addition, the inclusion criteria 
restricted that each dataset was obtained from a peer-reviewed study and contained a minimum of 
20 usable microarray samples (Figure 7). 
 
 
Figure 7 - Dataset Inclusion Criteria: Selection method used for the inclusion of Affymetrix 
datasets utilized in the analyses in this study. 
 
3.3.2 Normalization and differential expression  
For Affymetrix chips, raw microarray CEL files were read using the platform-compatible custom 
ENTREZG CDF file (version 12) [117] in order to obtain Entrez gene intensities.  Where 
multiple replicates from the same source were available, the gene intensities were averaged across 
replicates.  Nineteen out of thirty-one datasets contained samples for both the normal and cancer 
tissues and therefore could be used in meta-analysis.  Individual datasets were background 
adjusted normalized with median polish using the robust multi-array analysis (RMA) in 
MATLAB [62].  For each tissue, the corresponding log-transformed data were transferred into R 
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[118] and the metaGEM package [46] was utilized to conduct the meta-analysis using inverse 
variance (IV1; Figure 8).  The false discovery rate (FDR) was set at 0.001%.  Moreover, the samr 
package [119] in R was used to conduct the significance analysis of microarrays (SAM) test [75] 
on each individual dataset.  A hundred permutations were performed and results were restricted to 
significant genes with an FDR of 0. 
 
While IV analyzes each dataset separately before combining the results, SAM can be applied to 
previously merged data.  This merger was achieved by using the refRMA algorithm [63], 
designed for large microarray datasets to compute the robust multichip averages.  Background 
adjustment was applied to each array.  Quantile normalization was performed on a 909-array 
training set composed of all HG-U133 Plus 2.0 arrays used in this study.  Median polished 
outputs of the training set was finally used to adjust the normalized gene intensities thus allowing 
for the integration of data from all three platforms together, limiting results to the 9,409 genes 
common to these platforms.  A merged SAM test was then applied to the combined data of each 
tissue using the same datasets included in the IV1 test based on the aforementioned parameters 
(100 permutations and 0 FDR). 
 
As noted above, the IV test is limited to datasets that contain both cancer and normal tissues.  The 
merged SAM method, however, allows for the inclusion of datasets containing solely normal or 
solely cancer samples.  Thus, to test the effect of adding such datasets, microarray samples from 
all datasets of the same tissue were combined together and another series of SAM analyses were 
applied using the same test parameters as above.  For the purpose of this research, the first set of 
SAM tests, based on the data from the 19 datasets containing both normal and cancer tissues, is 
referred to as SAM1 (Figure 8).  The second method in which all samples from the 31 datasets 
could be utilized is denoted as SAM2 (Figure 8). For each tissue, the lists of top 400 differentially 
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expressed genes from the IV and both SAM tests were selected.  These gene lists were used to 
identify significantly enriched KEGG pathways at a p-value ≤ 0.05 using DAVID Bioinformatics 
resources [120-121]. 
 
3.3.3 Common transcriptional profiles across all five tissue types 
To identify consistent changes that are associated with multiple cancer tissue types, an IV1 test 
was conducted on all 19 Affymetrix datasets containing both cancer and normal samples together, 
regardless of tissue type.  Similarly, a SAM test was performed on the same samples (SAM1) and 
another SAM test was applied to all 1,768 available Affymetrix samples from the five tissues 
considered (SAM2).  The same test parameters were used as previously mentioned.  After 
determining the genes that behave consistently across all the different cancer types, the top 400 
genes were selected from the gene lists produced by each of the methods.  Enriched KEGG 
pathways were identified for all lists at a p-value cutoff of 0.05. 
 
3.3.4 Expanding IV analysis to cDNA data 
An additional five datasets using cDNA microarray platforms were obtained from GEO.  The 
datasets contained cancer versus normal samples from colon, kidney and lung tissues for a total of 
292 cancer and 169 normal samples.  No publicly-accessible data could be found for the other 
two tissues.  The IV analyses for these three tissues as well as the combined tissue test were re-
run (IV2; Figure 8) to investigate the cost of excluding these datasets from the merged SAM 
approach that relies solely on Affymetrix data.  Similar test parameters were applied; restricting 
results to genes with an FDR less than 0.001% and top 400 gene lists were utilized for identifying 
enriched KEGG pathways, as described above. 
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Figure 8  - Analysis Workflow: Flowchart depicting the steps involved in each of the four 
analyses considered: IV1, IV2, SAM1 and SAM2 
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3.4 Results 
3.4.1 Datasets and approaches 
Three different clustering of microarray datasets were used to evaluate (a) the intersection of 
significant gene lists predicted by meta-analysis and merged SAM methods and (b) compare 
these predictions with research literature excluding microarray studies.  Cluster 1 is composed of 
Affymetrix microarray datasets containing both cancer and normal samples for five different 
cancer tissues (Table 1).  The gene set predictions resulting from analysis of this data with the use 
of meta-analysis and merged SAM are denoted as IV1 and SAM1, respectively.  Each dataset was 
analyzed separately for the IV1 test and a final gene list was produced based on the weighted 
results from the individual datasets.  The SAM1 test was applied to the same Affymetrix data 
from each tissue after their merger, with all samples being normalized together, regardless of 
dataset.  Cluster 2 of microarray datasets used in intersection analysis and literature comparison 
contained cDNA microarray datasets in addition to the Affymetrix data in Cluster 1.  The gene 
lists predicted by meta-analysis using these datasets were called IV2.  Cluster 2 was used to take 
full advantage of the capability of meta-analysis in integrating microarray datasets from different 
technologies.  Cluster 3 contained asymmetric Affymetrix data in addition to data in Cluster 1 
(Table 1). The gene list corresponding to Cluster 3 data predicted by merged SAM is referred to 
as SAM2.  Figure 9 shows the overall characteristics of the Affymetrix datasets used in the 
analysis.  The intersections of the predicted gene lists obtained with the two methods on the three 
different dataset clusters are summarized in Table 2. The table also presents the p-values 
corresponding to the intersections based on a hypergeometric test.  
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Table 1- Overview of Data and Results: Datasets and distribution of microarray samples from 
the 5 cancer types used.  Affyemtrix datasets containing both normal and cancer samples were 
utilized for the IV1 and SAM1 tests (sample cluster 1), IV2 contained all datasets used in IV1 in 
addition to all cDNA datasets (sample cluster 2), and all Affyemtrix datasets were merged for 
SAM2 analysis (sample cluster 3). (Platforms: A: HG-U133A, A2, HG-U133A2, P2: HG-U133 
Plus 2) 
Tissue  Accession # Normal Cancer Platform 
Colon  E-MTAB-57 22 25 A 
  GSE4107 10 12 P2 
  GSE4183 8 15 P2 
  E-MEXP-1224 0 55 A 
  E-MEXP-383 0 36 A 
  E-TABM-176 55 0 P2 
  GSE12945 0 36 A 
  GSE17538 0 232 P2 
  GSE6988 28 52 cDNA 
   Total: 123 463  
Kidney  E-TABM-282 11 16 P2 
  GSE11024† 12 60 P2 
  GSE11151 3 57 P2 
  GSE14762† 12 10 P2 
  GSE15641 23 57 A 
  GSE6344 10 10 A 
  GSE7023 12 35 P2 
  GSE10320 0 144 A 
  GSE11904 0 21 A2 
  GSE3 81 90 cDNA 
  GSE7367 24 24 cDNA 
   Total: 164 524  
Liver  GSE14323 19 47 A/A2 
  GSE6764 10 35 P2 
  E-TABM-292 0 32 A 
  E-TABM-36 0 57 A 
  GSE9843 0 69 P2 
   Total: 29 240  
Lung  E-MEXP-231 9 49 A 
  GSE10072 49 58 A 
  GSE7670 27 27 A 
  GSE10445 0 72 P2 
  GSE12667 0 75 P2 
  GSE2088 30 57 cDNA 
  GSE8596 6 69 cDNA 
   Total: 121 407  
Pancreas  E-MEXP-1121† 6 17 A 
  E-MEXP-950 11 14 A 
  GSE15471 39 39 P2 
  GSE16515 15 36 P2 
   Total: 71 106  
 
† Datasets included replicated samples 
 
1 1 
1 1 
1 1 
1 
3 1 
3 1 
3 1 
3 1 
2 1 
2 1 
1 1 
2 1 
3 1 
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Figure 9 - Overview of Affymetrix Microarray Datasets Used: Distribution of all Affymetrix 
microarray data used based on the number of cancer versus normal samples in each dataset.  
Datasets used for IV1/SAM1 test are shown inside the ellipse.  Additional datasets included in 
SAM2 only are located on axes  
 
3.4.2 IV meta-analysis and merged SAM overlap significantly in results 
As in previous microarray studies of cancer [40, 122-127], the gene lists produced by the two 
approaches used in this study indicate significant alterations of the transcriptional profile as the 
tissue is transformed from the normal to the cancer state, with up to thousands of genes possibly 
undergoing statistically significant expression changes.  While the two methods applied to the 
three dataset clusters produced different lists of significant genes for each of the five tissues under 
consideration, there was a considerable overlap in the results (Table 2). The significance of the 
intersection between predicted gene lists increased consistently as the number of top-ranked 
genes used in comparison were increased from 10 to 400.  In colon tissue, the overlap with IV1 
was confined to 338 significant genes instead of 400, since that was the total number of genes 
passing the test criteria.  At the 400 gene level p-values of the IV1/SAM1 intersection ranged 
from 2.66E-26 in pancreas to 8.42E-181 in lung, while the most significant overlap in IV1/SAM2 
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was in kidney (p-value = 1.02E-134).  Comparison of the results of the two SAM methods 
produced even larger commonalities in the gene lists identified.  Apart from the colon tissue, 
there was at least 60% overlap between the top 400 gene lists generated by the two SAM 
methods, for any given comparison.  The match between the two SAM results became less 
pronounced with sharp increases in the number of samples added in SAM2.  Nevertheless, even 
with 506 colon cancer samples included in SAM2 as opposed to the 92 used in SAM1, the 
overlap between the two methods (176 genes) remained significant.  The overlap between IV1 
and IV2 varied largely among the top ranked 400 genes with a minimum overlap of 144 genes in 
lung tissue and a maximum overlap of 355 genes in kidney, resulting in vanishing p-values in the 
latter case (Table 2). 
 
To identify significantly altered genes across the five considered tissue types, the datasets from 
all tissues were pooled together.  Again, SAM2 included additional datasets with cancer or 
normal samples only.  Similarly, the significance of the overlap between the results increased as 
more top-ranked genes were considered, with p-values equal to 6.82E-97 and 2.80E-103 for the 
intersection at the top 400 genes level in IV1/SAM1 and IV1/SAM2, respectively (Table 2). 
 
3.4.3 Cell cycle pathway is commonly enriched in cancers 
The cellular pathways that were statistically enriched in the top 400 cancer-associated genes from 
the multiple tissues under consideration were identified using the DAVID Bioinformatics 
Resources’ functional annotation tool as described in the Methods section.  Enriched KEGG 
pathways common to at least two tissue types within a given test method or significantly 
associated with the combined 5-tissue comparisons are shown in Figure 10.  The cell cycle 
pathway was statistically enriched in IV1, IV2, SAM1 and SAM2 gene lists across all tissue types 
(Figure 11).  Among the key changes in the cell cycle in normal to cancer transition are the 
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differential expression of cyclins (A and B) and cyclin-dependent kinases (CDK1 and CDK4/6 
complex).  CDKs are the core of the regulatory apparatus of the cell cycle progression as changes 
in the kinases and cyclins drive the cell from one stage of the cell cycle to another [128].   
 
 
Figure 10 - Enriched KEGG Pathways: A list of KEGG pathways, shown in pink, that appear 
to be statistically enriched according to the top 400 genes from IV1, IV2, SAM1 and SAM2 at a 
p-value cutoff of 0.05.  Results are limited to pathways independently enriched in at least two of 
the or in the combined test including all tissues. 
 
In addition, the p53 signaling pathway and purine metabolism were significantly enriched in all-
tissue analyses of both IV tests and SAM2.  Pyrimidine metabolism is also enriched for the 
merged SAM2 significant genes while SAM1 genes are associated with ECM-receptor interaction 
and glycolysis/gluconeogenesis pathways.  At the tissue level, some of the metabolic pathways 
were common to both kidney and colon cancers (butanoate and nitrogen metabolism).  
Complement and coagulation cascades were enriched in four out of the five tissues under study. 
These results show that both methods of integration are capable of reproducing a significant 
portion of the research literature on cellular pathways activated in cancer. 
40 
 
Table 2 - Overlap in Top-Ranked Genes:  The overlap among n top-ranked genes between the IV1 and SAM1/SAM2 tests are shown as well as 
the corresponding p-values of the intersection.  Overlaps of top 400 genes between the similar approaches (IV1/IV2 and SAM1/SAM2) are also 
shown. 
IV1  SAM1 
n Colon Kidney Liver Lung Pancreas All 
Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value 
10 3 1.01E-07 0 0.989487 5 9.98E-14 2 4.49E-05 0 0.989487 0 0.989487 
50 11 8.67E-16 5 5.71E-06 17 7.85E-28 14 1.44E-21 8 1.49E-10 6 2.05E-07 
100 26 4.68E-30 23 3.04E-25 24 8.09E-27 34 4.21E-44 17 1.93E-16 18 7.94E-18 
200 62 1.88E-57 68 1.57E-66 53 9.78E-45 93 2.56E-109 34 8.96E-22 64 2.00E-60 
300 109 2.48E-91 106 4.38E-87 89 1.69E-64 146 5.40E-150 51 7.65E-24 103 6.46E-83 
400 132* 3.74E-98 146 1.41E-104 119 7.44E-72 198 8.42E-181 71 2.66E-26 140 6.82E-97 
 
IV1  SAM2 
n Colon Kidney Liver Lung Pancreas All       
 Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value 
10 3 1.01E-07 0 0.989487 4 1.31E-10 2 4.49E-05 0 0.989487 0 0.989487 
50 12 1.17E-17 5 5.71E-06 12 1.17E-17 8 1.49E-10 8 1.49E-10 5 5.71E-06 
100 32 1.97E-40 23 3.04E-25 24 8.09E-27 28 2.09E-33 17 1.93E-16 21 3.50E-22 
200 67 5.51E-65 66 1.88E-63 43 5.97E-32 69 4.34E-68 34 8.96E-22 65 6.22E-62 
300 111 3.32E-94 116 1.54E-101 60 4.00E-32 101 3.52E-80 51 7.65E-24 101 3.52E-80 
400 124* 9.02E-88 168 1.02E-134 86 1.19E-38 149 1.67E-108 71 2.66E-26 145 2.80E-103 
 
IV1  IV2 
n Colon Kidney Liver Lung Pancreas All       
 Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value 
400 163* 1.39E-186 355 0 No data - 144 3.97E-140 No data - 280 0 
 
SAM1  SAM2 
n Colon Kidney Liver Lung Pancreas All       
 Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value Overlap P-Value 
400 176 1.92E-146 284 0 253 6.86E-281 241 3.15E-257 No data - 262 2.34E-299 
 
* Only 338 genes are used for colon IV1
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Figure 11 - Cell Cycle Pathway: Differentially expressed genes involved in the cell cycle are shown in pink.  Genes are ranked among the top 
400 genes by at least one of the statistical approaches used (IV1, IV2, SAM1 and/or SAM2), based on analyses of all five tissues together. 
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3.4.4 Microarray results match cancer research literature with low p-values 
Next, the SAM1, SAM2, IV1, and IV2 top four hundred gene lists were tested for PubMed hits 
associated with cancer. An automated PubMed abstract search was conducted for the genes in the 
aforementioned lists, excluding those abstracts that belonged to microarray-based research.  Also 
excluded were abstracts that did not contain the word “cancer”. A gene had to have at least one 
such PubMed abstract match to be considered as a literature search hit.  The number of successful 
hits produced from the merged SAM methods and the IV tests intersected the research literature 
with significantly higher coverage than would be expected for randomly generated gene lists 
(Figure 12). The p-values shown in Figure 12 for the top 300 and 400 genes for all three methods 
were computed by using control gene lists obtained from the same Affymetrix platforms by 
randomly selecting lists of equal size (300 or 400) and averaging the number of hits over 100 
iterations.  The p-values for each tissue were then calculated using a normal distribution given the 
mean and standard deviation parameters of the randomly generated data.  The p-value for the 
colon IV1 in the top 400 gene list was adjusted to a hundred iterations of 338 randomly chosen 
genes to account for the maximum available number of genes.  The merged SAM methods 
produced gene lists that matched the research literature more accurately than the gene lists 
produced by the IV tests in four out of the five tissues under consideration.  Both SAM1 and 
SAM2 also produced more significant p-values per tissue than the average p-value obtained from 
the SAM tests performed on the individual datasets for a given tissue (data not shown).  The 
addition of single sample-type datasets resulted in fewer literature-associated gene lists than the 
SAM1 approach; however, the results improved when considering the top 400 genes as opposed 
to the top 300.  Note also that PubMed hits on gene lists presented by meta-analysis and merged 
SAM approaches fell inside and outside the intersections.  For example, the case of colon cancer 
in IV1 and SAM1 gene lists. There were 93 hits on IV1  SAM1 (p = 1.19E-07), 103 hits on IV1 
- IV1  SAM1 (p = 5.09E-02); and 205 hits on SAM1 - IV1  SAM1 (p = 2.32E-23). 
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Figure 12 - Literature Search Results: Histogram representing p-values of the number of top-
ranked genes with at least 1 PubMed abstract relating the genes to cancer research from a non-
microarray study according to each of the four test procedures: IV1 (gray), IV2 (yellow), SAM1 
(blue) and SAM2 (pink).  P-values are calculated based on expected data from a hundred random 
gene lists obtained from the platform and similarly related to non-microarray cancer literature.  .  
The horizontal line represents a p-value cutoff of 0.0001. 
* P-values adjusted to maximum number of available top genes. 
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As an additional control, the next top 400 genes (ranks 401-800) in each list, if available, were 
subjected to a similar PubMed abstract search.  The p-values representing the results revealed 
decreased literature coverage of these genes compared to the first top 400 genes in all cases 
except for SAM2 results in lung tissue.  In this test, the majority of the IV results (except for lung 
and pancreas) dropped below the 0.0001 p-value threshold marked by a horizontal black line in 
Figure 12. 
 
3.5 Discussion  
Meta-analysis approaches applied to microarray data aim to increase the statistical power of the 
results as well as to increase the reproducibility of individual studies [46].  Typical meta-analysis 
approaches combine results of independent datasets to produce a generalized outcome across 
these datasets. Meta-analysis approaches require both perturbed and control data within the same 
microarray datasets under consideration. However, the recent dramatic increase in publicly 
accessible microarray samples is mainly due to datasets containing no data on normal tissue. 
Noting that microarray samples on normal tissue are available in other public datasets, the idea of 
picking samples from different datasets obtained with same/similar microarray chips and 
normalizing them together before the identification of significantly altered genes in normal to 
cancer comparison was explored.  The resulting merged SAM sacrifices the use of data from 
other platforms. However, it could be potentially useful for integrated analysis of cancer 
microarray datasets for which much of the available data is highly asymmetric.  
 
One reason for asymmetry in the current public access microarray data is that the goals of global 
gene expression quantification in cancer research shifted towards identifying significant genes 
associated with cancer subtypes [39, 129-132]. The merged SAM analysis presented here is 
applicable to any microarray inquiry where there is a perturbed state (say cancer subtype 1) and 
45 
 
control state (cancer subtype 2).  The method of integration was applied to cases where there was 
plenty of data for both meta-analysis and merged data approaches.  Even when one aims to 
uncover differences in gene expression profiles between two cancer subtypes, it is often useful to 
consider such differences between subtypes and control normal tissue samples [122].  Such triple 
comparisons reveal the original basis for the subtype differences that stem from normal to cancer 
transformations. 
 
A quick study of the GEO database clearly shows that microarray data for hormone-associated 
solid cancers such as breast, prostate and ovarian cancers are highly asymmetric. The more recent 
datasets increasingly come from studies for which one cancer subtype is compared to another 
cancer subtype and as a result contain no data from normal samples. The five tissue types 
presented were chosen in this study because of the availability of data that could be used for both 
merged SAM and meta-analysis approaches. Previous studies have addressed the possible 
problems that arise from combining data across different technologies [133-134]. We have used 
the datasets obtained with similar chips to compare the performance of meta-analysis and merged 
the SAM approaches.  The direct integration of data preceding the analysis as in the case of the 
merged SAM overcomes the problems associated with small sample sizes in individual studies. 
While data merging across similar chips sacrifices the inclusion of some of the genes not 
common to all platforms, it provides additional robustness since all samples are normalized 
together as opposed to being normalized separately per dataset [135]. 
 
The meta-analysis and merged SAM approaches yielded significant gene lists with intersecting 
common gene subsets that could not be plausibly obtained by chance.  Both approaches matched 
automated PubMed abstract searches of research literature (excluding microarray studies) with 
very low p-values for random occurrence. However, the merged SAM approach replicated the 
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existing literature much more accurately than the meta-analysis approach in five of the six cases 
under study. Addition of cDNA arrays into meta-analysis resulted in reduced overlap with the 
cancer literature.  Meanwhile, the inclusion of asymmetric datasets also produced slightly less 
statistically significant results in merged SAM analyses; nevertheless, the approach still generated 
results that were at least as significant as the meta-analyses, again surpassing meta-analysis in 
five out of the six cases.  Despite the addition of hundreds of samples from asymmetric sets, the 
merged SAM continued to perform well, matching literature as well as results of symmetric 
microarray data.  Moreover, the match between microarray lists and the literature became less 
pronounced as lesser-ranked significant genes (401 – 800) were used in the comparison.  The 
gene lists obtained in all the tests were further validated by associating them with functional 
annotation through KEGG pathways.  While individually each tissue possessed a unique list of 
pathways and processes with which it was associated, overall, cell division appeared to be the 
common driving factor to all tissues, as would be expected. 
 
The automated text searches was used as an instrument for validation of the prediction value of 
the two different approaches to integrating microarray data associated with cancer.  Typical 
validation used in microarray analysis for illustrating relevance of gene list to disease state under 
consideration is usually via partitioning the dataset into learning, testing/validation subsets in a 
supervised learning approach [136-138]. However, it is relatively easy to differentiate between 
cancer and normal tissue with a variety of gene sets, but in many cases, such sets are laboratory 
specific [139]. Research literature in cancer is rich with data on genes associated with this disease 
and the bulk of such data was collected by using research tools other than microarrays, and 
therefore, automated text search constituted an independent means of validating the microarray 
results. 
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PubMed hits on gene lists produced by meta-analysis and merged SAM approaches fall on the 
intersections of such lists as well as outside the intersections, suggesting the use of both 
approaches whenever data is available.  The top ranked 400 genes in both cases are highly 
statistically enriched with PubMed hits and for which the intersection between the two 
approaches had typically the lowest p-value. When considering the role of well studied genes 
such as hub genes or genes in public access cellular pathways, projecting both gene lists onto 
known pathways to generate new hypothesis for experimental verification is a straightforward 
process.  The merged SAM technique provides a unique opportunity to obtain a candidate list for 
genes associated with a perturbed state in cases where the public microarray data is largely 
asymmetric. 
 
3.6 Conclusion  
Typical meta-analysis approaches allow for the use of various platforms at the expense of 
utilizing large amounts of data that exist in datasets containing either normal or cancer tissues 
only.  The merged SAM approaches in the study were shown to reproduce much of the known 
cancer literature while effectively being applied to asymmetrical microarray datasets.  Hence, this 
approach can be extended and applied to various other diseases.  While many of the genes in 
these lists have already been associated with cancer, the merged SAM approach sheds light on 
new genes that could play a pivotal role in cancer pathogenesis.  
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Chapter 4: Large-scale integration of microarray data reveals genes and pathways common 
to multiple cancer types 
 
4.1 Summary 
This chapter discusses the commonalities in aberrant gene expression that are shared by cancers 
arising in different tissue types through the use of microarray data.  The global gene expression 
analysis of cancer and healthy tissues typically results in large numbers of significantly altered 
SAM genes.  Such data, however, has been difficult to interpret due to the high level of variation 
of gene lists across laboratories and the small sample sizes used in individual studies.  For this 
research, the compiled microarray data was obtained from 84 laboratories using samples that 
were hybridized on the same platform family, resulting in a database containing 1043 healthy 
tissue samples and 4900 cancer samples for 13 different tissue types.  The primary cancers 
considered were adrenal gland, brain, breast, cervix, colon, kidney, liver, lung, ovary, pancreas, 
prostate and skin and stomach tissues.  The data was normalized together and analyzed in subsets 
for the discovery of genes involved in normal to cancer transformations.  This integrated 
approach produced top 400 ranked SAM gene lists for each of the thirteen cancer types.  These 
lists were highly statistically enriched with genes already associated with cancer in research 
publications excluding microarray studies (p < 1.31 E - 12).  The genes MTIM and RRM2 
appeared in nine and TOP2A in eight lists of significantly altered genes in cancer.  In total, there 
were 132 genes present in at least four gene lists, eleven of which had not been previously 
associated with cancer.  The list contains 17 metal ion and 15 adenyl ribonucleotide binding 
proteins, 6 kinases and 6 transcription factors.  These results point to the value of integrating 
microarray data in the study of combination drug therapies targeting metastasis. 
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4.2 Background 
Tens of thousands of microarray samples have accumulated in public access databases in the last 
decade [96-98].  A large portion of such data is cancer-specific and therefore holds the promise of 
cancer-associated gene discovery based on thousands of samples (not tens or hundreds).  Much of 
the cancer-associated microarray data in public domains comes without control samples.  In fact, 
the data in GEO is highly asymmetric, containing datasets with cancer microarray samples only 
and other datasets containing samples for healthy tissues but not cancer tissues.  Conventional 
meta-analysis approaches of integrating data, where laboratory results are combined after the 
datasets are independently analyzed, would not be useful in drastically increasing the sample 
sizes in microarray analysis of cancer.  Such analyses require the presence of both cancer and 
normal tissue samples in the same microarray dataset.  
 
In this study, a large-scale approach was used to integrate microarray data from multiple 
laboratories by normalizing them together and then using the Significance Analysis of Microarray 
(SAM) method [75].  This allowed for the identification of list of genes that are significantly 
altered in cancer compared to normal, specific for thirteen distinct tissues.  This methodology is 
grounded on previous studies that revealed the predictive potential of integrated microarray data. 
Large-scale meta-analysis techniques applied to cancer have already been adopted by a few 
groups [47, 84, 113-114], focusing on a single tissue type.  Other studies merged all cancer 
microarray data regardless of tissue type into one group and controls into another [48, 116] to 
identify gene sets associated with common cancer mechanisms.   The merge SAM approach is 
unusual when compared to the typical meta-analysis methods but it allows for the integration of 
asymmetric microarray data for global gene expression.  The various previously used methods 
reflect the purpose of the study undertaken, and despite the paper trail on the general 
methodology used, the question still arises as to the validity of the results from this research.  
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This study addresses the question regarding the extent to which the currently available microarray 
data has the potential to replicate the research literature on the molecular mechanisms of cancer. 
The automated text search algorithms utilized point to high-level coincidence between the 
generated gene lists and the cancer-associated genes determined from the non-microarray 
research literature.   
 
Using nearly 6,000 microarray samples, this study identifies 132 genes that are highly 
significantly associated with at least four distinct cancer types.  This research also presents a set 
of 270 genes that appear to be highly significant in comparisons of datasets consisting of cancer 
and normal tissues independent of tissue type.  These two sets have 74 genes in common and will 
potentially contribute to a more detailed annotation of the genes in the cancer bioinformatics 
databases.  This study points to the value of large-scale compilation of microarray data in cancer 
research, as the inclusion of large amounts of microarray data from different labs helps eliminate 
the effects of lab-specific noise to increase the reliability of the results [107]. 
 
4.3 Materials and Methods 
4.3.1 Microarray dataset selection and normalization 
An Affymetrix microarray database was constructed for normal and cancer samples obtained 
from 13 different solid tissues.  The tissues considered were: adrenal gland, brain, breast, cervix, 
colon, kidney, liver, lung, ovary, pancreas, prostate, skin and stomach.  The microarray data 
contained a total of 4,900 cancer and 1,043 normal tissue samples acquired from 84 labs.  All the 
data was obtained from the publically accessible Gene Expression Omnibus [96-97] and Array 
Express [98] online repositories.  The inclusion criteria restricted the use of datasets hybridized 
specifically on one of the three comparable Affymetrix platforms (HG-U133A, HG-U133A 2.0, 
and the HG-U133 Plus 2.0), where raw data CEL files were available, with at least 20 usable 
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microarray samples.  In addition, the results from the datasets should have been previously 
published in a peer-reviewed study.  No differentiation was made with respect to the different 
malignancies obtained from the same tissue. 
 
The data was normalized using the refRMA algorithm [63], utilizing the platform-compatible 
custom ENTREZG CDF files (version 12) [117] in order to obtain Entrez gene intensities.  
Background adjustment was applied and quantile normalization was performed on a 909-array 
training set that was then applied to compute the probe-level quantiles for the remaining data.  
Median polishing of the training set was finally used to adjust the normalized probe intensities of 
the remaining data.  Data was then filtered to remove the genes not shared by the three platforms.  
Finally, the gene intensities of replicate samples obtained from the same source were averaged 
across replicates.  All data pre-processing was performed in MATLAB [62]. 
 
4.3.2 Differential gene expression 
The differential expression of genes between cancer tissues and the corresponding controls was 
investigated using the Significance Analysis of Microarrays by utilizing the samr package [119] 
in R [118]. The SAM test was applied individually to the microarray datasets specific to each of 
the thirteen tissues under consideration.  For each SAM test, a hundred random iterations were 
performed and the false discovery rate (FDR) was constrained to zero. 
 
In addition, a general normal versus cancer test was conducted.  In order to avoid over-
representation and dominance of certain tissues, ten arrays were randomly chosen from both the 
normal and tumor samples of each tissue to produce two datasets (cancer, control) for SAM 
analysis.  The number ten was determined by the smallest sample size available for any tissue 
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(adrenal normal tissue).  SAM genes were then identified following the aforementioned criteria.  
Again, the random selection and differential expression process was repeated a hundred times. 
 
4.3.3 Functional annotation of top ranked and conserved genes 
The lists of top 400 SAM genes were obtained for each of the 13 tissues.  The cutoff (top 400) 
was chosen in order to optimize the match between the predicted SAM lists and lists of cancer 
associated genes obtained by via automated text search of non-microarray PubMed abstracts.  An 
enriched KEGG pathway profile was produced for each of the 13 tissues individually, at a p-value 
≤ 0.05 using DAVID Bioinformatics resources. 
 
4.3.4 Consistent differential expression across tissues 
Among the top 400 gene lists provided for each tissue, a subset of genes that were consistently 
differentially expressed was determined.  These genes were selected provided they appeared to be 
significantly altered in at least 4 of the 13 tissues. Moreover, the top 400 genes from the general 
normal-cancer comparisons were obtained for each of the 100 iterations.  The frequency of 
occurrence of each of the genes appearing in any of the lists was calculated to determine those 
genes whose changes in expression were most concordant.  The results of the two approaches 
were then compared. 
 
4.3.5 Cancer literature annotation of identified significant SAM genes 
To determine which genes from the SAM lists were known to be associated with cancer, an 
automated text search was performed.  For all the genes in the microarray platform, a search of 
the gene symbol and cancer was conducted in PubMed abstracts.  The results were limited to non-
microarray literature.  In addition, all literature papers associated with each of these genes as 
provided by the NCBI ftp site were obtained.  A list of PubMed IDs of all cancer non-microarray 
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literature were then acquired and was used to further determine which genes had been previously 
associated with cancer.  Results from the two approaches were combined to provide a 
comprehensive coverage of the known cancer literature.  The SAM lists were then annotated with 
these results, identifying those genes that were cited in relation to cancer at least once from those 
that had no cancer association.  As a control, a hundred random gene lists from the same platform 
of equal size to the SAM lists under consideration were obtained.  The number of cancer-related 
genes in each iteration was determined, and the mean and standard deviation were calculated 
from these values to obtain the parameters of a normal distribution.  The expected value and the 
standard deviation were then used to compute the p-values for the significant association of each 
of our cancer gene lists with the known non-microarray literature. 
 
4.4 Results 
4.4.1 Dataset 
Nearly six thousand microarray samples were used to identify significant gene lists involving 
normal to cancer transformations in 13 distinct human tissue types.  The distribution of samples 
across each tissue is shown in Table 3.  Overall, there were 4900 cancer samples and 1043 normal 
tissue microarray samples. The largest sample sets in the database belonged to breast, brain, 
colon, and kidney.  Sample distributions were asymmetric, with many more cancer samples than 
normal tissue samples.  Moreover, in order to increase sample sizes, datasets with only cancer or 
only normal tissue samples were added to the large-scale datasets.  This approach eliminated the 
use of microarray meta-analysis where each dataset is normalized and analyzed separately.  On 
the other hand, the merged SAM analysis used here best fits the recent trend of asymmetric 
growth in cancer samples in public-access microarray data.  Restriction of analysis to comparable 
microarray chips allowed for the normalization and analysis of samples in an integrated fashion 
without significantly reducing the number of samples that could be used in the analysis.    
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Table 3 - Data Summary: Dataset accessions and number of normal and cancer microarray 
samples used for each of the 13 tissue analyses 
Tissue Accession # Normal Cancer Total 
Adrenal Gland GSE10927 10 33 43 
 
E-TABM-311 0 34 34 
  Total: 10 67 77 
Brain GSE12907 3 21 24 
 
GSE13041 0 175 175 
 
GSE11882 173 0 173 
 
GSE4271 0 100 100 
 
GSE3790 87 0 87 
 
GSE4412 0 85 85 
 
GSE5675 0 41 41 
 
GSE2817 0 30 30 
 
GSE17612 23 0 23 
  Total: 286 452 738 
Breast GSE10780 143 42 185 
 
GSE10797 10 56 66 
 
GSE3744 7 40 47 
 
E-TABM-276 13 18 31 
 
GSE5764 20 10 30 
 
GSE16873 12 12 24 
 
E-MEXP-882 4 19 23 
 
GSE8977 15 7 22 
 
GSE4922 0 289 289 
 
GSE2034 0 286 286 
 
GSE11121 0 200 200 
 
GSE7390 0 198 198 
 
GSE1456 0 159 159 
 
GSE2603 0 99 99 
 
GSE6532 0 73 73 
 
GSE5327 0 58 58 
 
GSE5847 0 55 55 
 
GSE1561 0 49 49 
 
GSE12276 0 48 48 
 
GSE12763 0 30 30 
 
GSE6596 0 24 24 
 
GSE13787 0 23 23 
  Total: 224 1795 2019 
Cervix GSE9750 21 33 54 
 
GSE7803 10 21 31 
 
GSE6791 8 20 28 
 
GSE5787 0 33 33 
  Total: 39 107 146 
Colon E-MTAB-57 22 25 47 
 
GSE4183 8 15 23 
 
GSE4107 10 12 22 
 
GSE17538 0 232 232 
 
E-TABM-176 55 0 55 
 
E-MEXP-1224 0 55 55 
 
GSE12945 0 36 36 
 
E-MEXP-383 0 36 36 
  Total: 95 411 506 
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Table 3 (continued) 
 
Kidney GSE15641 23 57 80 
 
GSE11151 3 57 60 
 
E-TABM-282 11 16 27 
 
GSE14762 12 10 22 
 
GSE6344 10 10 20 
 
GSE10320 0 144 144 
 
GSE11024 0 60 60 
 
GSE7023 0 35 35 
 
GSE11904 0 21 21 
  Total: 59 410 469 
Liver GSE14323 19 47 66 
 
GSE6764 10 35 45 
 
GSE9843 0 69 69 
 
E-TABM-36 0 57 57 
 
E-TABM-292 0 32 32 
  Total: 29 240 269 
Lung GSE10072 49 58 107 
 
E-MEXP-231 9 49 58 
 
GSE7670 27 27 54 
 
GSE12667 0 75 75 
 
GSE10445 0 72 72 
  Total: 85 281 366 
Ovary GSE6008 4 99 103 
 
GSE18520 10 53 63 
 
GSE9891 0 189 189 
 
GSE14764 0 80 80 
 
E-MEXP-935 0 27 27 
 
GSE9455 0 20 20 
  Total: 14 468 482 
Pancreas GSE15471 39 39 78 
 
GSE16515 15 36 51 
 
E-MEXP-950 11 14 25 
 
E-MEXP-1121 6 17 23 
  Total: 71 106 177 
Prostate GSE6956 18 69 87 
 
E-TABM-26 13 44 57 
 
GSE17356 0 27 27 
 
GSE2443 0 20 20 
  Total: 31 160 191 
Skin GSE7553 5 82 87 
 
GSE13355 64 0 64 
 
GSE8401 0 31 31 
  Total: 69 113 182 
Stomach GSE13911 31 38 69 
 
GSE15460 0 229 229 
 
GSE8167 0 23 23 
  Total: 31 290 321 
Overall Total: 1043 4900 5943 
 
 
 
56 
 
4.4.2 SAM genes and their match with research literature 
The SAM gene lists obtained for the thirteen distinct human tissues by setting the false discovery 
rate to zero varied in length depending on the tissue.  However, the top 400 genes in each list 
matched well with the cancer-associated gene literature obtained from experiments excluding 
microarrays (Table 4).  The automated text search algorithm described in the methods section 
showed that nearly 80% of the genes in these lists were previously associated with cancer in non-
microarray studies.  P-values for the occurrence of these matches by chance were estimated by 
generating randomly chosen gene lists from the microarray chip, and varied from a low of 2.86 E-
33 for adrenal tissue to 6.99 E-12 in brain tissue.  Next, genes that occurred in multiple tissue-
specific lists were selected and their match with the literature was similarly difficult to explain by 
chance events.  These results indicate the potential of microarray studies based on large sample 
sizes to regenerate much of the known literature associated with cancer.  The choice of top 400 as 
a cut off is somehow arbitrary, however, results indicated that the match between microarray 
predictions and literature was nearly optimal at this particular cutoff value (data not shown). 
 
4.4.3 Cellular pathways enriched for top 400 SAM genes 
The top 400 SAM gene lists from all tissue types were projected onto KEGG [101] cellular 
pathways to evaluate their statistical enrichment using DAVID [120-121].  Results shown in 
Figure 13  indicate the statistically enriched cellular pathways previously associated with cancer 
such as the glycine, serine, and threonine metabolism, PPAR signaling pathway, DNA 
replication, and ECM-receptor interaction.  The variation in the catalog of enriched pathways 
from tissue to tissue is a reflection of the tissue-specific dimensions of cancer.  It must also be 
noted that pathways not enriched for some tissues and enriched for others still included 
considerable amounts of SAM genes even for those tissues in which the pathway p-values were 
not significant.  
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Table 4 - Overview of Results: Number of significant genes among the top 400 genes for the 13 tissues appearing at least in one (T 400), two (T2 
400) or three (T3 400) tissues.  Also shown are the number and corresponding percentages and p-values of these gene that have been associated 
with cancer in the non-microarray literature found in PubMed (PM) abstracts 
 T 400 PM 400 (%) P-Value T2 400 PM2 400 (%) P-Value T3 400 PM3 400 (%) P-Value 
Adrenal 400 343 85.8 2.86E-33 235 203 86.4 8.26E-15 132 119 90.2 4.26E-14 
Brain 400 300 75.0 6.99E-12 277 237 85.6 8.54E-19 154 135 87.7 1.63E-12 
Breast 400 344 86.0 6.53E-34 153 117 76.5 2.76E-05 56 45 80.4 3.26E-03 
Cervix 400 335 83.8 2.21E-28 234 202 86.3 6.01E-14 106 96 90.6 1.39E-10 
Colon 400 324 81.0 2.45E-22 243 208 85.6 3.91E-15 130 117 90.0 1.74E-11 
Kidney 400 333 83.3 3.18E-27 230 194 84.3 4.86E-12 126 112 88.9 1.57E-10 
Liver 400 328 82.0 1.91E-24 194 161 83.0 1.73E-11 91 83 91.2 5.21E-09 
Lung 400 325 81.3 7.44E-23 224 193 86.2 2.02E-14 119 105 88.2 2.41E-08 
Ovary 400 323 80.8 7.92E-22 231 198 85.7 3.24E-15 115 106 92.2 3.81E-15 
Pancreas 400 337 84.3 1.45E-29 229 202 88.2 6.28E-16 110 99 90.0 7.26E-11 
Prostate 400 307 76.8 1.52E-14 197 148 75.1 8.67E-06 76 60 78.9 6.77E-04 
Skin 400 324 81.0 2.45E-22 247 206 83.4 3.78E-15 127 107 84.3 1.91E-07 
Stomach 400 302 75.5 1.31E-12 184 144 78.3 4.81E-09 72 59 81.9 5.80E-05 
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Figure 13 - Pathway Profiles of Different Cancer Tissues: Heat map showing the significant 
pathway profiles for each of the thirteen cancer tissues considered.  The color-scale represents the 
–log of the p-value for the pathway enrichment using a p-value cutoff of 0.05  
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4.4.4 SAM genes in multiple gene lists 
A total of 132 genes appeared in at least four of the top 400 SAM genes out of the 13 total tissue 
types considered. All, with the exception of 11 genes were previously affiliated with cancer in the 
non-microarray based research literature. These genes are listed in Table 5a along with the 
affiliated tissue types in which they appeared among the top 400 SAM genes. The table also 
identifies the up- and downregulation of the genes in each cancer tissue and annotates approved 
and experimental drugs targeting some of these genes as obtained from DrugBank [140-141]. The 
genes MTIM and RRM2 appear in nine and TOP2A appears in eight out of the thirteen tissues. 
These genes are followed in the list by genes that appear in at least seven cancer types: ADH1B, 
CDC20, CFD, GSTM5, CLEC3B, PRC1, and MELK, ABCA8, UBE2C, KIF4A, and RACGAP1.  
Among this list, TOP2A is currently targeted by seven approved drugs (Table 5b).  The gene 
EPHX2 is targeted by tamoxifen in the treatment of breast cancer, and ESSRG by 
Diethylstilbestrol for prostate cancer.  Meanwhile, experimental drugs targeting CDC2 and 
TUBA1B are going through approval processes. 
 
Shown in Table 6a are those top 400 SAM genes found in at least four lists but have not been 
previously associated with cancer. The gene LPCAT1 appears in the lists for cervix, colon, 
kidney, pancreas and stomach.  This enzyme mediates conversion of LPC to PC, thereby playing 
a pivotal role in respiratory physiology.  Among, the genes in Table 6a are found in four SAM 
gene lists out of the thirteen tissue types under study, only BBOX1 was associated with approved 
drug targets. Further studies are needed to annotate the potential roles of these genes in the 
progression of cancer. 
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Table 5 - Annotation of Commonly Altered Genes: a) List of genes differentially expressed in 
at least 4 tissues and have been previously associated with cancer in non-microarray literature.  
The tissues in which the genes are altered are shown where regular font indicated upregulation 
and italics represents downregulation in cancer compared to normal tissue. Entrez IDs shown in 
bold represent genes that appeared to be significant in the general normal/cancer comparisons. b) 
List of approved and experimental cancer drugs targeting commonly altered genes 
a) 
Entrez ID Gene Symbol Gene Name Tissues 
4499 MT1M Metallothionein 1M Adrenal, Breast, Colon, Kidney, 
Liver, Lung, Pancreas, Prostate, 
Stomach 
6241 RRM2 Ribonucleotide reductase M2 polypeptide Adrenal, Breast, Cervix, Colon, 
Kidney, Liver, Lung, Pancreas, 
Prostate 
7153 TOP2A Topoisomerase (DNA) II alpha 170kDa Adrenal, Breast, Cervix, Kidney, 
Liver, Lung, Ovary, Pancreas 
125 ADH1B Alcohol dehydrogenase 1B (class I), beta 
polypeptide 
Adrenal, Breast, Colon, Kidney, 
Lung, Ovary, Skin 
991 CDC20 Cell division cycle 20 homolog (S. cerevisiae) Adrenal, Breast, Cervix, Liver, 
Lung, Ovary, Pancreas 
1675 CFD Complement factor D (adipsin) Adrenal, Breast, Cervix, Colon, 
Ovary, Prostate, Skin 
2949 GSTM5 Glutathione S-transferase M5 Adrenal, Breast, Cervix, Lung, 
Ovary, Prostate, Skin 
7123 CLEC3B C-type lectin domain family 3, member B Adrenal, Breast, Colon, Kidney, 
Lung, Prostate, Skin 
9055 PRC1 Protein regulator of cytokinesis 1 Adrenal, Cervix, Kidney, Liver, 
Lung, Pancreas, Prostate 
9833 MELK Maternal embryonic leucine zipper kinase Adrenal, Breast, Cervix, Colon, 
Lung, Ovary, Pancreas 
10351 ABCA8 ATP-binding cassette, sub-family A (ABC1), 
member 8 
Breast, Cervix, Colon, Kidney, 
Lung, Ovary, Skin 
11065 UBE2C Ubiquitin-conjugating enzyme E2C Adrenal, Breast, Cervix, Colon, 
Liver, Ovary, Skin 
24137 KIF4A Kinesin family member 4A Adrenal, Breast, Cervix, Colon, 
Liver, Ovary, Skin 
29127 RACGAP1 Rac GTPase activating protein 1 Adrenal, Cervix, Kidney, Liver, 
Lung, Ovary, Pancreas 
316 AOX1 Aldehyde oxidase 1 Adrenal, Kidney, Ovary, 
Pancreas, Prostate, Skin 
701 BUB1B BUB1 budding uninhibited by benzimidazoles 
1 homolog beta (yeast) 
Adrenal, Cervix, Kidney, Liver, 
Lung, Pancreas 
4306 NR3C2 Nuclear receptor subfamily 3, group C, 
member 2 
Breast, Colon, Kidney, Ovary, 
Pancreas, Skin 
4674 NAP1L2 Nucleosome assembly protein 1-like 2 Brain, Breast, Colon, Kidney, 
Ovary, Skin 
4886 NPY1R Neuropeptide Y receptor Y1 Adrenal, Colon, Kidney, Liver, 
Ovary, Skin 
6696 SPP1 Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 
1) 
Adrenal, Cervix, Colon, Lung, 
Skin, Stomach 
6790 AURKA Aurora kinase A Adrenal, Cervix, Colon, Kidney, 
Liver, Lung 
9133 CCNB2 Cyclin B2 Adrenal, Breast, Cervix, Liver, 
Lung, Ovary 
9232 PTTG1 Pituitary tumor-transforming 1 Adrenal, Cervix, Colon, Ovary, 
Pancreas, Skin 
9314 KLF4 Kruppel-like factor 4 (gut) Adrenal, Breast, Cervix, Colon, 
Lung, Skin 
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Table 5a (continued) 
Entrez ID Gene Symbol Gene Name Tissues 
11130 ZWINT ZW10 interactor Adrenal, Cervix, Liver, Lung, 
Pancreas, Prostate 
22974 TPX2 TPX2, microtubule-associated, homolog 
(Xenopus laevis) 
Adrenal, Breast, Cervix, Colon, 
Ovary, Skin 
51203 NUSAP1 Nucleolar and spindle associated protein 1 Breast, Cervix, Kidney, Liver, 
Lung, Pancreas 
54810 GIPC2 GIPC PDZ domain containing family, member 
2 
Adrenal, Breast, Kidney, Liver, 
Ovary, Skin 
84981 MGC14376 Hypothetical protein MGC14376 Adrenal, Breast, Colon, Kidney, 
Liver, Ovary 
38 ACAT1 Acetyl-Coenzyme A acetyltransferase 1 
(acetoacetyl Coenzyme A thiolase) 
Adrenal, Colon, Kidney, Liver, 
Pancreas 
762 CA4 Carbonic anhydrase IV Breast, Colon, Kidney, Lung, 
Pancreas 
983 CDC2 Cell division cycle 2, G1 to S and G2 to M Adrenal, Breast, Cervix, Liver, 
Ovary 
2053 EPHX2 Epoxide hydrolase 2, cytoplasmic Adrenal, Colon, Kidney, 
Pancreas, Skin 
2348 FOLR1 Folate receptor 1 (adult) Adrenal, Breast, Kidney, Ovary, 
Stomach 
3075 CFH Complement factor H Adrenal, Breast, Cervix, Ovary, 
Skin 
3248 HPGD Hydroxyprostaglandin dehydrogenase 15-
(NAD) 
Cervix, Colon, Kidney, Liver, 
Stomach 
4128 MAOA Monoamine oxidase A Breast, Colon, Kidney, Ovary, 
Skin 
4171 MCM2 Minichromosome maintenance complex 
component 2 
Cervix, Colon, Liver, Pancreas, 
Prostate 
4246 SCGB2A1 Secretoglobin, family 2A, member 1 Colon, Ovary, Prostate, Skin, 
Stomach 
4494 MT1F Metallothionein 1F Colon, Kidney, Liver, Pancreas, 
Stomach 
4495 MT1G Metallothionein 1G Colon, Kidney, Liver, Pancreas, 
Stomach 
5950 RBP4 Retinol binding protein 4, plasma Adrenal, Brain, Breast, Kidney, 
Skin 
6776 STAT5A Signal transducer and activator of transcription 
5A 
Adrenal, Breast, Ovary, 
Prostate, Stomach 
7102 TSPAN7 Tetraspanin 7 Breast, Colon, Kidney, Liver, 
Lung 
9073 CLDN8 Claudin 8 Breast, Cervix, Colon, Kidney, 
Skin 
9173 IL1RL1 Interleukin 1 receptor-like 1 Adrenal, Kidney, Liver, Lung, 
Skin 
9768 KIAA0101 KIAA0101 Adrenal, Breast, Cervix, Liver, 
Lung 
9936 CD302 CD302 molecule Adrenal, Breast, Liver, Ovary, 
Skin 
10051 SMC4 Structural maintenance of chromosomes 4 Adrenal, Brain, Cervix, Kidney, 
Pancreas 
10894 LYVE1 Lymphatic vessel endothelial hyaluronan 
receptor 1 
Breast, Liver, Lung, Ovary, Skin 
23492 CBX7 Chromobox homolog 7 Brain, Breast, Lung, Ovary, Skin 
35 ACADS Acyl-Coenzyme A dehydrogenase, C-2 to C-3 
short chain 
Colon, Liver, Pancreas, Prostate 
290 ANPEP Alanyl (membrane) aminopeptidase 
(aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 
Breast, Colon, Kidney, Pancreas 
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Table 5a (continued) 
Entrez ID Gene Symbol Gene Name Tissues 
994 CDC25B Cell division cycle 25 homolog B (S. pombe) Cervix, Colon, Pancreas, Skin 
1012 CDH13 Cadherin 13, H-cadherin (heart) Adrenal, Liver, Lung, Stomach 
1113 CHGA Chromogranin A (parathyroid secretory 
protein 1) 
Adrenal, Brain, Colon, Stomach 
1164 CKS2 CDC28 protein kinase regulatory subunit 2 Breast, Cervix, Ovary, Pancreas 
1282 COL4A1 Collagen, type IV, alpha 1 Liver, Ovary, Pancreas, Stomach 
1410 CRYAB Crystallin, alpha B Breast, Cervix, Lung, Prostate 
1776 DNASE1L3 Deoxyribonuclease I-like 3 Adrenal, Colon, Kidney, Liver 
1805 DPT Dermatopontin Adrenal, Breast, Prostate, Skin 
1827 RCAN1 Regulator of calcineurin 1 Breast, Colon, Kidney, Liver 
2023 ENO1 Enolase 1, (alpha) Adrenal, Lung, Ovary, Stomach 
2104 ESRRG Estrogen-related receptor gamma Kidney, Pancreas, Skin, Stomach 
2146 EZH2 Enhancer of zeste homolog 2 (Drosophila) Cervix, Kidney, Lung, Prostate 
2273 FHL1 Four and a half LIM domains 1 Breast, Colon, Lung, Skin 
2305 FOXM1 Forkhead box M1 Cervix, Colon, Ovary, Skin 
2690 GHR Growth hormone receptor Breast, Liver, Ovary, Skin 
2819 GPD1 Glycerol-3-phosphate dehydrogenase 1 
(soluble) 
Breast, Kidney, Lung, Pancreas 
3131 HLF Hepatic leukemia factor Brain, Breast, Ovary, Skin 
3223 HOXC6 Homeobox C6 Cervix, Ovary, Pancreas, 
Stomach 
3479 IGF1 Insulin-like growth factor 1 (somatomedin C) Breast, Liver, Prostate, Skin 
3489 IGFBP6 Insulin-like growth factor binding protein 6 Adrenal, Breast, Ovary, Skin 
3815 KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog 
Breast, Colon, Ovary, Prostate 
3957 LGALS2 Lectin, galactoside-binding, soluble, 2 Colon, Ovary, Pancreas, 
Prostate 
4147 MATN2 Matrilin 2 Adrenal, Breast, Prostate, Skin 
4501 MT1X Metallothionein 1X Colon, Kidney, Liver, Skin 
4692 NDN Necdin homolog (mouse) Breast, Cervix, Ovary, Prostate 
4830 NME1 Non-metastatic cells 1, protein (NM23A) 
expressed in 
Colon, Kidney, Lung, Stomach 
5050 PAFAH1B3 Platelet-activating factor acetylhydrolase, 
isoform Ib, gamma subunit 29kDa 
Adrenal, Breast, Lung, Skin 
5101 PCDH9 Protocadherin 9 Adrenal, Breast, Ovary, Prostate 
5121 PCP4 Purkinje cell protein 4 Brain, Kidney, Prostate, Skin 
5348 FXYD1 FXYD domain containing ion transport 
regulator 1 (phospholemman) 
Breast, Colon, Lung, Skin 
5577 PRKAR2B Protein kinase, cAMP-dependent, regulatory, 
type II, beta 
Colon, Liver, Ovary, Skin 
5734 PTGER4 Prostaglandin E receptor 4 (subtype EP4) Adrenal, Breast, Colon, 
Pancreas 
5984 RFC4 Replication factor C (activator 1) 4, 37kDa Adrenal, Cervix, Kidney, Lung 
6338 SCNN1B Sodium channel, nonvoltage-gated 1, beta 
(Liddle syndrome) 
Cervix, Colon, Kidney, Stomach 
6456 SH3GL2 SH3-domain GRB2-like 2 Brain, Kidney, Ovary, Stomach 
6659 SOX4 SRY (sex determining region Y)-box 4 Brain, Cervix, Liver, Lung 
7045 TGFBI Transforming growth factor, beta-induced, 
68kDa 
Cervix, Colon, Liver, Pancreas 
7049 TGFBR3 Transforming growth factor, beta receptor III Breast, Kidney, Lung, Skin 
7058 THBS2 Thrombospondin 2 Colon, Lung, Pancreas, Stomach 
7070 THY1 Thy-1 cell surface antigen Colon, Liver, Pancreas, Stomach 
7122 CLDN5 Claudin 5 (transmembrane protein deleted in 
velocardiofacial syndrome) 
Breast, Lung, Prostate, Skin 
7433 VIPR1 Vasoactive intestinal peptide receptor 1 Brain, Colon, Liver, Lung 
7704 ZBTB16 Zinc finger and BTB domain containing 16 Breast, Lung, Ovary, Skin 
9104 RGN Regucalcin (senescence marker protein-30) Breast, Kidney, Ovary, Pancreas 
9413 C9orf61 Chromosome 9 open reading frame 61 Breast, Cervix, Lung, Stomach 
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Table 5a (continued) 
Entrez ID Gene Symbol Gene Name Tissues 
8418 CMAH Cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase (CMP-N-acetylneuraminate 
monooxygenase) 
Adrenal, Colon, Ovary, Skin 
8611 PPAP2A Phosphatidic acid phosphatase type 2A Breast, Colon, Ovary, Skin 
9104 RGN Regucalcin (senescence marker protein-30) Breast, Kidney, Ovary, Pancreas 
9413 C9orf61 Chromosome 9 open reading frame 61 Breast, Cervix, Lung, Stomach 
9601 PDIA4 Protein disulfide isomerase family A, member 
4 
Brain, Cervix, Lung, Ovary 
9636 ISG15 ISG15 ubiquitin-like modifier Breast, Cervix, Liver, Pancreas 
9837 GINS1 GINS complex subunit 1 (Psf1 homolog) Adrenal, Cervix, Liver, Lung 
10376 TUBA1B Tubulin, alpha 1b Cervix, Kidney, Pancreas, 
Stomach 
10417 SPON2 Spondin 2, extracellular matrix protein Adrenal, Colon, Liver, Pancreas 
10797 MTHFD2 Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
Brain, Cervix, Lung, Ovary 
11170 FAM107A Family with sequence similarity 107, member 
A 
Breast, Lung, Pancreas, 
Prostate 
11335 CBX3 Chromobox homolog 3 (HP1 gamma 
homolog, Drosophila) 
Cervix, Colon, Kidney, Lung 
23213 SULF1 Sulfatase 1 Colon, Lung, Pancreas, Stomach 
25802 LMOD1 Leiomodin 1 (smooth muscle) Adrenal, Breast, Lung, Skin 
25928 SOSTDC1 Sclerostin domain containing 1 Breast, Cervix, Lung, Stomach 
26586 CKAP2 Cytoskeleton associated protein 2 Colon, Kidney, Liver, Pancreas 
27284 SULT1B1 Sulfotransferase family, cytosolic, 1B, 
member 1 
Cervix, Colon, Skin, Stomach 
51053 GMNN Geminin, DNA replication inhibitor Adrenal, Cervix, Liver, Lung 
51659 GINS2 GINS complex subunit 2 (Psf2 homolog) Adrenal, Cervix, Kidney, Lung 
53405 CLIC5 Chloride intracellular channel 5 Breast, Colon, Kidney, Lung 
55165 CEP55 Centrosomal protein 55kDa Cervix, Colon, Lung, Pancreas 
57088 PLSCR4 Phospholipid scramblase 4 Breast, Liver, Ovary, Skin 
79728 PALB2 Partner and localizer of BRCA2 Adrenal, Lung, Pancreas, 
Stomach 
84560 MT4 Metallothionein 4 Adrenal, Kidney, Liver, 
Pancreas 
283298 OLFML1 Olfactomedin-like 1 Adrenal, Breast, Ovary, Skin 
 
 
b) 
Entrez ID Gene Symbol Status Drug Name Indication 
7153 TOP2A Approved Dexrazoxane For reducing the incidence and severity 
of cardiomyopathy associated with 
doxorubicin administration in women 
with metastatic breast cancer 
  Approved Valrubicin For the treatment of cancer of the 
bladder. 
  Approved Teniposide Treatment of refractory acute 
lymphoblastic leukaemia 
  Approved Epirubicin For use as a component of adjuvant 
therapy in patients with evidence of 
axillary node tumor involvement 
following resection of primary breast 
cancer 
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Table 5b (continued) 
Entrez ID Gene Symbol Status Drug Name Indication 
  Approved Etoposide For use in combination with other 
chemotherapeutic agents in the treatment of 
refractory testicular tumors and as first line 
treatment in patients with small cell lung 
cancer. Also used to treat other malignancies 
such as lymphoma, non-lymphocytic 
leukemia, and glioblastoma multiforme. 
  Approved Idarubicin For the treatment of acute myeloid leukemia 
(AML) in adults. This includes French-
American-British (FAB) classifications M1 
through M7. 
  Approved Lucanthone Intended for use as a radiation sensitizer in 
the treatment of brain cancer. 
2053 EPHX2 Approved Tamoxifen For the treatment of breast cancer 
2104 ESRRG Approved Diethylstilbestrol Used in the treatment of prostate cancer 
983 CDC2 Experimental Flavopiridol n/a 
10376 TUBA1B Experimental Epothilone B n/a 
  Experimental Epothilone D n/a 
 
Table 6 - Annotation of New Cancer Genes: a) List of genes that are differentially expressed in 
at least 4 tissues and have not been previously associated with cancer in non-microarray 
literature.  The tissues in which the genes are altered are shown where regular font indicated 
upregulation and italics represents downregulation in cancer compared to normal tissue. Entrez 
IDs shown in bold represent genes that appeared to be significant in the general normal/cancer 
comparisons.  b) List of approved cancer drugs targeting commonly altered genes that have not 
been previously associated with cancer 
a) 
Entrez ID Gene Symbol Gene Name Tissues 
79888 LPCAT1 Lysophosphatidylcholine acyltransferase 1 Cervix, Colon, Kidney, 
Pancreas, Stomach 
33 ACADL Acyl-Coenzyme A dehydrogenase, long chain Lung, Ovary, Pancreas, Skin 
2824 GPM6B Glycoprotein M6B Adrenal, Breast, Lung, Prostate 
8424 BBOX1 Butyrobetaine (gamma), 2-oxoglutarate 
dioxygenase (gamma-butyrobetaine 
hydroxylase) 1 
Breast, Cervix, Kidney, Skin 
9452 ITM2A Integral membrane protein 2A Breast, Colon, Ovary, Skin 
9631 NUP155 Nucleoporin 155kDa Adrenal, Cervix, Lung, Stomach 
10391 CORO2B Coronin, actin binding protein, 2B Adrenal, Breast, Lung, Ovary 
27147 DENND2A DENN/MADD domain containing 2A Breast, Colon, Lung, Prostate 
51660 BRP44L Brain protein 44-like Kidney, Liver, Skin, Stomach 
51751 HIGD1B HIG1 domain family, member 1B Adrenal, Liver, Lung, Prostate 
65983 GRAMD3 GRAM domain containing 3 Adrenal, Breast, Colon, Skin 
 
 
b) 
Entrez ID Gene Symbol Status Drug Name Indication 
8424 BBOX1 Approved Vitamin C Used to treat vitamin C deficiency, scurvy, delayed 
wound and bone healing, urine acidification, and in 
general as an antioxidant. It has also been 
suggested to be an effective antiviral agent. 
8424 BBOX1 Approved Succinic acid For nutritional supplementation, also for treating 
dietary shortage or imbalance 
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A second, alternative method was used to identify those genes that are common in the general 
pathway of cancer. A cancer microarray database and a control database were generated 
randomly selecting ten samples from each tissue type, resulting in a set of 130 cancer and 130 
control samples.  SAM analysis was then used to identify the top 400 significant genes, repeating 
this operation a hundred times.  The union of these hundred gene lists each containing 400 genes 
produced 1,411 genes of which 44 are in the KEGG’s pathways in cancer.  The union of genes 
from the first 50 iterations produces a list of 1,235 genes indicating that additional iterations 
produce few new SAM genes.  The p-value associated with the intersection with the pathways in 
cancer using the hypergeometric test using the platform genes as the background is 0.0196.  Of 
the 1411, 271 genes are found in at least 70% of the iterations, of which 12 are found in the 
pathways of cancer with corresponding p-values of 0.0208.  Moreover, 74 genes out of the 271 
appeared among the 132 genes listed in Table 5 and Table 6.  The p-value for this overlap 
is 9.0763E-082.  The list of 271 genes is provided as Additional File 2. Taken together with genes 
in Table 5 and Table 6, they can be used to extend and further annotate the general pathways of 
cancer. 
 
4.5 Discussion 
In this study, nearly six thousand microarray samples were obtained from comparable Affymetrix 
platforms to investigate the commonalities as well as the tissue specific components of normal to 
cancer transformation in thirteen distinct tissue types.  It was possible to obtain such a large 
sample size through the addition of highly asymmetric datasets into the microarray sample pool. 
Mainly, those datasets with large numbers of cancer samples and small numbers (including zero) 
of control samples and vice versa, were considered. Otherwise, out of the thirteen tissue types 
under study, only the breast, colon, kidney, and pancreas tissues had three or more different 
datasets that included at least ten cancer and ten control samples.  
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This approach is unusual in the sense that it does not fit typical meta-scale analyses [46-48, 86, 
105-106] where each dataset needs to have both disease and control samples in sufficient 
numbers and datasets are normalized and analyzed separately for significant genes.  Using the 
meta-analysis approach, Ramasamy et al. [46] analyzed 21 distinct microarray datasets from 14 
different cancer types comprising 419 control and 973 samples.  The minimum sample size for 
cancer and control in their study was seven and some of the tissue types such as renal tissue 
appeared only in one dataset in their collection.  The advantage of this method is the flexibility 
concerning the multiple platforms that can be incorporated and thereby increasing sample size 
through acceptance of several platforms.  Because this research focuses on a set of comparable 
platforms, the results are not directly comparable.  Nevertheless, Ramasamy et al. [46] published 
five upregulated and five downregulated genes as most significantly associated with cancer. 
Among this list of ten, four genes (TMEM136, RBM15, FGD4 and KIAA1881) are not part of the 
minimal platform considered in this study, suggesting that as the data in public-access microarray 
repositories grow, datasets used in the proposed approach will be restricted to the latest version of 
platforms containing many more probes.  Of the remaining six genes, the top 400 lists from this 
research confirmed the downregulation of PRKAR2B and GPM6B in four different tissues. Genes 
MYOM2 and RBCK1 in their ten gene list were SAM genes in multiple lists in this study but were 
in the top 400 only in the liver gene list.  Similarly, ALG3 did not appear in any of the top 400 
gene lists but was significantly upregulated in six of the thirteen tissues in the complete SAM 
lists.  The last gene in their list, IRAK1 was a top ten ranking gene in the pancreas SAM gene list, 
however, this gene was downregulated in pancreas as well as five more tissues in this study, as 
opposed to the upregulated notation presented to the gene by Ramasamy et al. [46].  Note that this 
research contained 106 cancer and 71 normal pancreatic tissue microarray samples as opposed to 
the 12 tumor and 7 normal microarray samples in [46].  It is not feasible to summarize the 
comparison with a p-value because the gene list presented in [46] contains only ten genes 
whereas the various gene lists produce by this research contain hundreds of genes.  Nevertheless, 
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it is clear that the two approaches could potentially produce gene lists whose intersection is 
unlikely to be a random event.  
 
The proposed approach takes advantage of the rapid increase of asymmetric data in public-access 
microarray repositories.  Moreover, gene lists predicted using this large asymmetric data 
reproduces much of the research literature on cancer-associated genes obtained by experimental 
methods other than microarray.  This analysis predicts 132 genes as significantly altered in 
normal to cancer transformation in at least four tissue types and out of this list, 121 were 
previously annotated in the literature as cancer-related.  The remaining eleven genes comprise 
potential targets for further studies in cancer research.  Note also that 74 out of the 132 genes in 
the list also appear in 70% of the SAM gene lists generated by comparing normal and cancer 
datasets comprising of randomly chosen ten samples from each tissue type.  The two gene lists 
presented in this study for cancer-associated genes with multiple tissue specificity will further 
contribute to the annotation of pathways of cancer.  Recently emerging annotation-based 
microarray data tools such as A-MADMAN [142] will help in the compilation process of large-
scale microarray data for studying complex diseases, and for biomarker and drug development. 
 
4.6 Conclusion 
In this study, almost 6,000 microarray samples were obtained and a total of 329 genes were 
identified that appeared as highly significant in normal to cancer transformation with regards to 
multiple cancer types.  The gene list consists largely of genes that have already been associated 
with cancer in research literature excluding microarray studies.  The list can be used in the 
detailed annotation of cancer pathways.  In addition due to the inclusion of numerous subtypes 
and cancer grades, the genes in this list can serve as potential targets for new drug development.  
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Chapter 5: Virus and host iron binding protein interactions 
 
5.1 Summary 
The intricate relationships that evolve between viruses, host iron binding proteins, cellular iron 
supplies and the immune response are the core of this chapter.  The regulation and utilization of 
iron in humans has evolved to a high degree of complexity.  Many of the basal pathways and 
cellular functions depend on iron as a component of iron binding proteins.  These proteins are 
therefore involved in a wide range of functions varying from energy metabolism to DNA 
synthesis to oxygen transport.  More importantly, iron binding proteins are also part of the human 
immune system.  Iron redox properties render it crucial yet potentially toxic.  As a result, iron 
homeostasis is necessary since iron is needed for maintaining a healthy system as well as a 
diseased one.  In general, viruses rely on host cellular machinery for their own replication.  
Consequently, sufficient iron quantities are essential to allow for efficient viral propagation.  Iron 
overloads have been observed in viral infections including HIV and hepatitis C and are generally 
associated with poor prognosis.  By using publicly accessible databases, human iron binding 
proteins were identified.  Microarray data on three viral infections: HIV, hepatitis C and influenza 
A were collected and analyzed to identify direct and indirect targets of these viral infections that 
are dependent on iron and therefore important for iron homeostasis.  Results revealed significant 
changes in the transcript levels of 101, 122, and 107 iron binding proteins in HIV, hepatitis C and 
influenza A, respectively.  These proteins appeared to be involved in biological processes related 
to cellular metabolism, oxidative stress response and immune system processes.  Moreover, the 
microarray results captured some of the known imperative changes induced by HIV-1 viruses that 
have been documented in the literature.  These outcomes emphasize the vitality of iron for 
sustaining viral demands as well as the critical role that iron recruited by the virus could 
potentially play in helping the virus escape the host’s immunes system. 
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5.2 Background 
Several fundamental cellular operations in living systems require the presence of iron ion binding 
proteins [143] and rely on the redox abilities of ferrous (Fe
2+
) and ferric (Fe
3+
) iron [144].  Iron 
ions act as a cofactor for enzymes involved in energy metabolism, DNA synthesis, replication and 
repair, transcription, and mRNA translation, rendering it essential for cells.  In addition, iron in 
hemoglobin and myoglobin binds oxygen allowing for its transport [143, 145].  The primary 
function of iron in living systems is therefore greatly dependent on its role in shuttling electrons 
between proteins and its flexibility for binding ligands in diverse orientations [143]. 
 
Iron also has a crucial role in immunity and immunosurveillance.  This is achieved through iron’s 
involvement in cell-mediated immune effector pathways and cytokine activities as well as its role 
in promoting immune cells’ growth [145-147], which can then affect the cells’ response to an 
invading pathogen.  In return, cytokines and radicals produced and released by the immune cells 
can control and regulate iron homeostasis, through transcriptional and post-transcriptional 
methods [145].  Hence, iron metabolism and the immune system possess a delicate relationship 
through which they can regulate one another. 
 
The link between the immune defense and iron metabolism is often targeted by infectious agents 
including the human immunodeficiency virus and hepatitis C [145, 148-149].  Viruses depend on 
host cells for their survival, and viral replication requires enhanced cellular metabolism for 
transcribing and translating viral genomes and proteins.  Since these processes depend on and 
require iron, the host cells have to contain a sufficient supply of iron to meet the demands [143].  
Iron accumulation can accompany the more advanced stages of HIV infection [148, 150], while 
increased iron storage in bone marrow macrophages could be associated with shorter survival 
times [151-152].  After an HIV infection, the virus reverse-transcribes its RNA into double-
stranded DNA which is then integrated into the host’s genome.  HIV kills target cells and alters 
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gene expression through the involvement of viral regulatory proteins (Tat, Rev, Nef), and many of 
the activities targeted by HIV are iron-dependent [148]. 
 
A number of recent studies focused on the role of iron in clinical progression of HIV infection. 
Elevated iron stores have been detected in HIV patients including those in brain, liver and 
muscles [148].  The effects of iron supplementation on HIV infection have also been studied 
[153], with research on pregnant women from Zimbabwe revealed that receiving iron 
supplementation was an independent predictor of higher viral load [154].  In a study on 
thalassemic HIV patients, the rate of progression of the disease was associated with 
desferroxamine and higher serum ferritin concentrations [155].  Meanwhile research on Belgian 
HIV cohort reported that haptoglobin 2-2 was related to increased iron storage, higher rates of 
viral replication and shortened survival [156].  Another study in Kenya found that iron 
supplementation reduced the rates of post-treatment reinfection, and that viral load was higher in 
patients receiving iron compared to the placebo group [157], while several other studies have 
agreed that iron overload resulted in decreased survival of HIV patients [158-160].   
 
Similar iron overload has been observed in hepatitis C patients.  Hepatitis C is known to cause 
liver injury and cancer, and while the process is not fully understood, the pathology seems to be 
driven by chronic inflammation.  Increased morbidity and mortality in hepatitis C patients has 
been associated with elevated levels of cellular iron, which behaves as a pro-inflammatory agent.  
Haemochromatosis can also result in chronic iron deposition in the liver, and has been associated 
with cirrhosis and injury that could lead to hepatocellular carcinoma.  While iron deposition can 
be the result of inherited defects in host genes involved in iron metabolism, the virus itself can 
also induce similar iron overloads.  Elevated levels of hydroxyl radicals are generated in the 
presence of excess iron.  Such radicals are highly reactive and can therefore cause damage to 
proteins, DNA and lipids within the cell [143, 149], thereby inflicting damage to the cell 
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membranes and the genome [149].  The oxidative stress can also result in mitochondrial 
dysfunction and cause liver satellite cells to produce collagen, contributing to the development of 
fibrosis.  Therefore, excess iron in hepatitis C patients can trigger an inflammatory environment 
that disturbs the liver’s normal function [143]. 
 
This research uses bioinformatics methods and publicly accessible molecular and functional 
genomics databases to identify the components of virus-host crosstalk involving host iron binding 
proteins.  The National Institute of Allergy & Infectious Diseases’ (NIAID) HIV-1, Human 
Protein Interaction Database [161-163] and molecular function annotation have provided 
knowledge for the identification of nodes in pathways leading to HIV viral replication associated 
with iron binding.  Results from HIV microarray analysis have confirmed viral effects on several 
key proteins including NADPH oxidase complex, ABCE1, IDO1 and ALOX5.  Differential gene 
expression analysis conducted on hepatitis C microarray data has also revealed significant overlap 
with HIV induced alterations to iron binding proteins.  Data obtained on influenza A virus was 
also tested, providing a control non-persistent infection to facilitate the understanding of how 
persistent viral infections influence iron homeostasis and evade the host’s immune system. 
 
5.3 Methods 
5.3.1 Identification of iron-associated proteins 
To determine the human proteins that are associated with iron binding a list of proteins annotated 
with the GO [102-103] molecular functions “iron ion binding” and “iron-sulfur cluster binding” 
were retrieved from the GO Consortium and DAVID Bioinformatics [120-121] databases. The 
summation list was checked against the literature and UniProtKB [164-165] database to confirm 
the functional association of these proteins with iron.  Only genes with RefSeq status of 
“REVIEWED” or “VALIDATED” were retained.  Moreover, 6 proteins were added as iron 
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binding based on a recent review on the role of iron-ion binding proteins in viral infections [143].  
The final list contained 299 iron binding proteins. 
 
5.3.2 Identifying direct HIV-1 iron binding protein targets 
To understand the interplay between HIV proteins and host proteins mediated by the function of 
iron within the cell, a list of proteins that are known to interact with HIV-1 proteins, either 
directly or indirectly, was obtained from the NIAID HIV-1, Human Protein Interaction Database 
[161-163] (Version: December 2009).  The list contained a total of 1433 human proteins 
corresponding to 68 types of different interactions with the viral proteome.  Proteins that were 
annotated as iron binding were identified within this list, to determine the iron-dependent proteins 
that are targeted by HIV-1. 
 
5.3.3 Microarray dataset selection on viral infections 
Changes in gene expression levels induced by HIV-1 infection were then investigated.  
Microarray datasets for healthy and HIV-1 infected CD4+ T-cells were collected from the Gene 
Expression Omnibus [96-97].  The details of the datasets used are shown in Table 7.  In summary, 
130 healthy and 21 HIV-1 infected CD4+ T-cell samples were collected.  In order to identify 
commonalities in interactions with iron ion binding host proteins, similar data were obtained for 
hepatitis C and influenza A infected PBMC cells as well as healthy controls.  The summary list of 
the datasets and the sample distribution is also presented in Table 7.  The microarray data was 
confined to datasets hybridized on the Affymetrix human microarray platforms HG-U133A, HG-
U133A2 and HG-U133 Plus 2.0, to allow for data merger due to the large overlap between these 
platforms.   
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Table 7 - Microarray Datasets: Microarray samples utilized in analysis of changes induced by 
viral infections. 
GEO Accession # Platform Healthy Samples Infected Samples 
HIV Infection: 
GSE6740 HG-U133A 5 10 
GSE9927 HG-U133 Plus 2.0 9 11 
GSE6338 HG-U133 Plus 2.0 5 0 
GSE7497 HG-U133A 16 0 
GSE8835 HG-U133A 12 0 
GSE10586 HG-U133 Plus 2.0 15 0 
GSE12079 HG-U133 Plus 2.0 4 0 
GSE13732 HG-U133 Plus 2.0 40 0 
GSE14879 HG-U133 Plus 2.0 10 0 
GSE14924 HG-U133 Plus 2.0 10 0 
GSE17354 HG-U133A 4 0 
Total  130 21 
Hepatitis C Infection: 
GSE7123 HG-U133A 0 59 
GSE11190 HG-U133 Plus 2.0 0 19 
GSE11342 HG-U133A 0 20 
Total  0 98 
Influenza A Infection: 
GSE6269 HG-U133A & Plus 2.0 6 25 
GSE17156 HG-U133A2 17 17 
Total  23 42 
Healthy PBMC: 
GSE8507 HG-U133 Plus 2.0 34 0 
GSE8650 HG-U133A 21 0 
GSE12839 HG-U133A 7 0 
GSE14895 HG-U133A2 11 0 
GSE15072 HG-U133A 8 0 
GSE16728 HG-U133 Plus 2.0 5 0 
Total  86 0 
 
 
5.3.4 Microarray data normalization and differential gene expression 
Raw .CEL files for all the samples were obtained and normalized using the refRMA [63] 
conducted in MATLAB .  A total of 909 diverse microarray samples from the HG-U133 Plus 2.0 
chip were used to train the data.  The normalization process included background adjustment, 
quantile normalization, and median polishing.  In addition, the custom ENTREZ CDF files 
(version 12) [117] were used in the normalization process in order to obtain Entrez gene 
intensities.  The outputs from the training set were then used to adjust the normalized gene 
intensities of the data utilized in this analysis.  The data from the common genes between the 
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three platforms were filtered and used for differential gene analysis.  Finally, where multiple 
samples were obtained from the same individual, average intensities were calculated from these 
samples prior to differential gene expression analysis. 
 
To identify the genes that exhibited changes in expression due to viral infection, the data was 
imported into R [118] and the Significance Analysis of Microarrays (SAM; [75]) test was applied 
using the samr package [119].  The test parameters were set to a hundred permutations of the 
analysis and the false discovery rate (FDR) was not allowed to exceed 6%.  Each viral infection 
data was compared to the corresponding healthy control data separately.  Among the significant 
genes satisfying these conditions, iron binding host proteins that appeared to be affected, directly 
or indirectly, by each of the viral infections at the transcriptional level were determined. 
 
5.3.5 Distribution of gene expression levels of iron binding proteins 
The inherent range of expression values for iron binding proteins at the transcript level was 
determined to understand their behavior within the normal state.  Intersecting the three microarray 
platforms results in fewer iron binding genes that can be studied.  Therefore, to obtain a full 
representation of the levels of gene expression in healthy tissues, only data hybridized on the HG-
U133 Plus 2 chip for uninfected CD4+ T-cells were utilized, as it is the largest of the three 
platforms used in this study.  Average intensity values were computed for each of the 17,726 
genes on the chip.  The data from the entire platform were clustered using the K-means clustering 
algorithm [166] into four groups depicting the genes’ level of expression: low, medium-low, 
medium-high and high.  The iron binding proteins were then mapped to their location within 
these clusters (Figure 14). 
 
75 
 
 
Figure 14 - Gene Expression Histogram: Distribution of Iron binding proteins (yellow) and 
HIV-interacting iron binding proteins (pink) with respect to all genes represented on the HG-
U133 Plus 2.0 microarray platform based on gene intenisties in normal CD4+ T-cells. 
 
5.4 Results 
5.4.1 Iron binding proteins are statistically enriched among HIV targeted host proteins. 
A total of 299 host proteins were identified as iron binding and among them 40 were previously 
annotated as HIV-1 interacting proteins (Figure 15a).  A hypergeometric test based on all proteins 
from NCBI as the background resulted in a p-value of 1.80E-12 for this overlap.  Iron-ion binding 
proteins are therefore statistically enriched among known HIV-1 interacting proteins, indicating 
the important role iron ions play in viral replication [143].  A list of those 40 proteins is provided 
in Table 9 depicting the HIV-1 proteins that target them and the types of interactions that occur 
between them. 
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Figure 15 - HIV-1/Iron Binding Proteins and Differential Gene Expression: a) Venn diagram 
representing the overlap between the iron-binding proteins used in this study and proteins in the 
HIV-1 Human PPI Database, and b) Fold change values for the 15 genes whose expression is 
altered in HIV-1 infection 
 
5.4.2 Gene expression analysis confirms the effect of HIV-1 infection on CD4+ T cells 
Among the 40 iron-associated HIV-interacting proteins identified, 15 appeared to be significantly 
enriched according to SAM analysis conducted on CD4+ T cells from HIV patients compared 
with healthy T cells.  Among those differentially expressed were 9 downregulated and 6 
upregulated genes as shown in Figure 15b.  The absolute fold change is shown after deducting 1.0 
from all values.  The behavior of these genes in the other viral conditions was also considered 
(Table 9).  Eight of the 15 differentially expressed genes in HIV-1 infections exhibited similar 
significant alterations in hepatitis C, compared to only three concurrent alterations in gene 
expression inflicted by influenza A infection. 
 
5.4.3 Significant commonalities in alteration induced by persistent viral infections on iron 
binding proteins 
The microarray platform used for analysis of differential gene expression contained information 
on transcript levels of 191 out of the 299 iron binding proteins.  Of these, 172 (90%) genes were 
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significantly altered in at least one type of viral infection, and a total of 43 genes appeared in all 
three SAM lists (Figure 16).  Moreover, the overlap between the different infections was as 
follows: 73 genes in HIV  Hepatitis C, 60 genes in HIV  Influenza A, and 68 genes in 
Hepatitis C  Influenza A.  Using a hypergeometric test with a 0.05 threshold, only the 
intersection between HIV and hepatitis C was significant with a p-value of 4.6E-03.  This 
highlights the similarities in HIV and hepatitis C as persistent infections, which is suggestive of 
their subsequent influences on the cellular machinery and immune system. 
 
 
Figure 16 – Differential Expression of Iron Binding Proteins Induced by Viral Infections: 
Venn diagram depicting the distribution of the 191 iron binding proteins present on the 
microarray platform according to differential expression in HIV, Hepatitis C, and Influenza A. 
 
To further investigate the roles of these proteins, all iron binding genes that were differentially 
expressed in at least one of the infection types considered were merged together.  Enriched 
KEGG pathways were identified using a p-value cutoff of 0.05.  Many of the common iron 
binding genes belong to the cytochrome P450 family.  Therefore, as the results in Table 8 reflect, 
several metabolic pathways are affected by these infections.  Retinol metabolism (Figure 17) 
contains the largest number of significantly altered genes, most of which are P450 enzymes.  Iron 
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is known to interact with several dietary components including retinol (vitamin A).  Retinol is 
essential for normal haematopoiesis and deficiencies have been associated with mild anaemia, 
poor immune response and delayed repair of damaged epithelial cells.  Such deficiencies can also 
affect the severity of some infectious diseases.  In addition, iron is necessary for retinol 
mobilization, and thus retinol and iron metabolism are closely interrelated [167]. 
 
Table 8 – Pathways Affected by Iron Binding Proteins: Enriched KEGG pathways associated 
with iron binding genes that were differentially expressed due to viral infection by HIV, Hepatitis 
C and/or Influenza A 
KEGG Metabolic Pathway Genes P-Value 
Retinol metabolism 17 3.80E-16 
Drug metabolism – Cytochrome P450 15 7.67E-12 
Linoleic acid metabolism 12 1.45E-11 
Arachidonic acid metabolism 14 4.81E-11 
Metabolism of xenobiotics by cytochrome P450 13 8.12E-10 
Steroid hormone biosynthesis 12 1.85E-09 
Drug metabolism 8 1.09E-05 
Tryptophan metabolism 7 1.52E-04 
Caffeine metabolism 4 4.62E-04 
Primary bile acid biosynthesis 5 5.60E-04 
Alzheimer's disease 12 7.47E-04 
Parkinson's disease 9 2.28E-03 
Porphyrin and chlorophyll metabolism 5 3.41E-03 
Steroid biosynthesis 4 8.66E-03 
Tyrosine metabolism 5 2.01E-02 
Citrate cycle (TCA cycle) 4 2.85E-02 
Arginine and proline metabolism 5 2.85E-02 
Oxidative phosphorylation 7 3.37E-02 
Biosynthesis of unsaturated fatty acids 3 4.66E-02 
 
 
Cytochrome P450 proteins are also the major enzymes involved in drug metabolism contributing 
to the metabolism of approximately 75% of drugs [168], including tamoxifen, cyclophosphamide, 
ifosfamide and methadone (Figure 18).  Drug doses are adjusted such that they can be cleared by 
the body at a reasonable rate.  Hence, alterations in the availability of P450 enzymes, directly 
affect the body’s ability to metabolize and clear drugs.  While inhibition of P450 proteins can 
result in drug accumulation, drug-drug interactions and drug toxicity, induction of cytochromes 
can result in faster drug clearance, interfering with the drug’s role and efficiency [168]. 
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Table 9 - Regulation of HIV-Interacting/Iron Binding Proteins: A list of 40 iron binding proteins that are known to directly interact with HIV 
proteins, the types of interactions and proteins they associate with.  The differential expression at the transcript level in HIV, Hepatitis C and 
Influenza A is shown: downregulated (), upregulated () and non-differentially expressed (●).  Expression level clusters, according to expression 
in healthy CD4+ T cells are also indicated: low (L), middle-low (ML), high-low (HL) and high (H). 
Gene Symbol Entrez ID Cluster HIV Hepatitis C Influenza A Interaction HIV Protein 
NOX4 50507 L ● ●  activated by Gp120 
NOX3 50508 L ● ●  activated by Gp120 
PTGS2 5743 L ● ● ● upregulated by 
upregulated by 
Gp120 
Tat 
TH 7054 L    downregulated by Tat 
NOX5 79400 L ● ● ● activated by Gp120 
NOS3 4846 ML ●  ● inhibited by 
upregulated by 
Tat 
Gp41 
LTF 4057 ML ● ● ● inhibits Gp120 
HFE 3077 ML ● ● ● downregulated by Nef 
NOX1 27035 ML ●   activated by Gp120 
IDO1 3620 ML   ● release induced by Gp120 
CYP27B1 1594 ML    activated by Matrix 
NOS1 4842 ML ● ●  inhibited by 
upregulated by 
Tat 
Gp41 
CYBB 1536 ML   ● inhibited by Capsid 
PTGS1 5742 ML ● ● ● upregulated by 
upregulated by 
Gp120 
Tat 
NOS2 4843 ML  ● ● inhibited by 
upregulated by 
upregulated by 
Tat 
Gp120 
Gp41 
ALOX5 240 ML   ● upregulated by Gp120 
PPP2CB 5516 ML    inhibits Tat 
ERCC2 2068 ML   ● binds Tat 
APP 351 MH   ● activated by 
inhibited by 
inhibits 
inhibits 
upregulated by 
Retropepsin 
Gp41 
Gp120 
Tat 
Tat 
CYCS 54205 MH ● ● ● released by Vpr 
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Table 9 (continued) 
Gene Symbol Entrez ID Cluster HIV Influenza A Hepatitis C Interaction HIV Protein 
CYP51A1 1595 MH    upregulated by Nef 
IKKE 9641 MH ● ● ● binds 
phosphorylated by 
Gp120 
Nef 
IKK1 1147 MH ● ● ● binds 
phosphorylated by 
Gp120 
Nef 
SDHB 6390 MH ● ●  binds Tat 
ABCE1 6059 MH  ●  associates with 
associates with 
Pr55 
Vif 
TFRC 7037 MH ● ● ● downregulated by 
downregulated by 
Gp120 
Nef 
HMOX2 3163 MH  ●  upregulated by Gp120 
IKK2 3551 MH ● ● ● binds 
phosphorylated by 
Gp120 
Nef 
GLRX2 51022 MH ● ●  activates Retropepsin 
CAT 847 MH ● ● ● inhibits Gp160 
PPP3CA 5530 MH  ●  activated by Tat 
PPP1CB 5500 MH ● ●  stimulates 
upregulated by 
Tat 
Gp120 
PPP3CC 5533 MH ● ● ● activated by Tat 
PPP1CA 5499 H  ●  downregulated by 
stimulates 
Gp120 
Tat 
CYC1 1537 H  ●  release induced by Vpr 
DOCK2 1794 H ●   associates with Nef 
PPP2CA 5515 H ● ●  inhibits Tat 
PPP3CB 5532 H ● ●  activated by Tat 
GLRX5 51218 H ●  ● activates Retropepsin 
PPP1CC 5501 H ● ● ● stimulates Tat 
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Figure 17 - Retinol Metabolism in Animals: Iron binding genes in KEGG's retinol metabolism pathway that are significantly altered by HIV 
(pink), Influenza A (blue) and Hepatitis C (purple) infections 
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Figure 18 - Drug Metabolism Cytochrome P450: Iron binding genes in KEGG's drug metabolism (Cytochrome P450) that are significantly 
altered by HIV (pink), Influenza (blue) and Hepatitis C (purple) infection 
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Figure 18 (continued)  
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Figure 18 (continued) 
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More information on the biological processes revealed the enrichment of oxidative stress 
response.  In addition, 12, 11 and 9 of the proteins in the HIV, hepatitis C, and influenza A lists, 
respectively, were involved in immune system response. This emphasizes the dual role viruses 
provoke on host cells in terms of metabolic demands and immune response.  Nonetheless, the 
behavior of these genes within the different infections sheds some meaningful insight on the 
differences between HIV/hepatitis C and influenza A.  For example, cytochrome B (CYBB) is 
downregulated in both HIV and hepatitis C, but no changes are observed in influenza.  CYBB is 
one of the down-stream proteins in the interferon-gamma (IFN-) mediated immune response, 
and its downregulation impairs the oxidative burst response and phagocytosis that are needed to 
fight infections [169].  ALOX5 and ABCE1 are also known to be direct HIV-1 target proteins, and 
similar changes were perceived in hepatitis C microarray results but not influenza A. 
 
5.5 Discussion 
Iron is a vital nutrient for most organisms.  It is universally present in the active site of iron 
binding proteins involved in oxygen transport, energy metabolism and respiratory pathways, 
DNA synthesis, and metabolite synthesis [143, 145, 170].  However, the reactive properties that 
typically make iron useful to these proteins also result in free iron being toxic [171].  Due to the 
high involvement of iron throughout the body’s cellular processes, cells commit complex systems 
to control the availability, reactivity and flux of iron in order to maintain a healthy cellular 
environment [144].   
 
The initial step for achieving homeostasis is through the regulation of iron absorption from the 
gut.  However the process of transporting iron to usage and storage sites is equally important, in 
addition to the roles of enterocytes and macrophages [144].  Monocytes and macrophages utilize 
different pathways to acquire iron.  These methods include transferrin-mediated uptake, 
transmembrane uptake of ferrous and ferric iron, obtaining iron through lactoferrin or ferritin 
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receptors, as well as through erythrophagocytosis.  As a result, the proliferation and 
differentiation of these cells are not affected by limiting the iron supply through one of these 
sources [145].   While iron is important and deficiencies result in aberrant cell growth and 
immune function, iron overload is similarly deleterious [144-145], affecting the proliferation and 
activation of T-cells, B-cells and natural killer cells [145, 172-173].  One mechanism through 
which iron loading can affect cells is by inhibiting IFN-  mediated pathways in macrophages, 
which causes them to lose their ability to kill intracellular pathogens [145].  Moreover, the lack of 
an iron excretory pathway highlights the importance of homeostatic mechanisms adopted by cells 
in order to balance out iron needs as opposed to iron overload as well as redox utility as opposed 
to resulting toxicity. 
 
Microarray data was retrieved to identify the alterations that the three viral infections considered, 
namely HIV, hepatitis C and influenza A induce, focusing interest on the differentially expressed 
iron binding proteins.  HIV and hepatitis C are persistent diseases that reside in the host and 
cannot be cured.  While influenza A infections can at times be fatal, the majority of people 
display uncomplicated, acute febrile respiratory symptoms that last around three to five days or 
exhibit no symptoms at all [174].  Hence, influenza was chosen as a control by comparing the 
changes this infection instigates to those brought about by HIV and/or hepatitis C.  This allows 
for a direct investigation of the role of iron in supporting general viral mechanisms.  Results 
revealed the significant changes at the transcriptional level of 101, 122 and 107 iron binding 
proteins in HIV, hepatitis C and influenza A, respectively.  Comparisons among these lists 
indicated over 50% overlap.  However, statistically only the overlap between HIV and hepatitis C 
was significant.  Further investigation of these three lists revealed the inclusion of several 
cytochrome P450 proteins, which were enriched in several metabolic pathways (Table 8).  This 
indicates the commonalities in the changes these viruses inflict on the cell to exploit the host’s 
machinery.   
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However, as noted above, some of the main known HIV-1 host protein targets that bind iron 
displayed similar changes in expression level in hepatitis C but not in influenza infected cells.  
This implicates that hepatitis C possibly utilizes similar mechanisms to evade the host’s immune 
response.  Among those proteins was CYBB which is part of the NADPH oxidase enzymatic 
complex.  NADPH oxidase is the main producer of superoxide anion (O2
-
) through the reduction 
of oxygen.  In the cell, superoxide dismutase then acts as an antioxidant by utilizing electrons 
from copper or zinc for the conversion of superoxide into hydrogen peroxide (H2O2).  In resting 
cells, the NADPH oxidase complex is typically dormant.  Monocytes and macrophages usually 
release increased levels of reactive oxygen species (ROS) as a response to certain stimuli.  The 
generation of high levels of ROS, referred to as respiratory burst, plays an important role in the 
host defense mechanism against pathogens [169, 175].  These reactive species are therefore 
involved in inflammatory processes, apoptosis, aging and carcinogenesis [176].  Iron is essential 
for the function of the NADPH oxidase complex with a heme-b acting as the prosthetic redox 
group in cytochrome b.  Iron deficiencies therefore result in reduced enzyme activity [177]. 
 
HIV-1 targets NADPH oxidase through various proteins.  First, Gp120 binds to CXC chemokine 
receptor 4 (CXCR4) which in turn activates the NAPDH oxidase complex resulting in increased 
expression of superoxide radicals and subsequent activation of neutral sphingomyelinase, 
inducing apoptosis and cell death [178].  On the other hand, Nef plays a time-dependent role in 
this process.  In the early stages, Nef is responsible for the induction of phosphorylation and cell-
membrane translocation of NCF1 and NCF2, hence activating NADPH oxidase, which results in 
the production of superoxide [169, 175]. Meanwhile, Gp160 also enhances the respiratory burst 
and oxidative stress through the production of H2O2 [176].  Within 10 hours, Nef inhibits NADPH 
oxidase resulting in a dysregulation in the production of ROS, impairing specific immune 
functions including the oxidative burst response and phagocytosis.  This in turn allows for the 
development of HIV-1 pathogenesis [169, 175].  In addition, the viral capsid has been shown to 
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inhibit the IFN-  induced accumulation of the cytochrome B heavy chain mRNA [179], and this 
inhibition is evident from the observed downregulation of CYBB in the microarray analysis. 
 
On the other hand, arachidonate 5-lipoxygenase (ALOX5) is a nonheme iron-containing 
dioxygenase that plays an important role in the biosynthesis of leukotrienes, namely the catalysis 
of the production of leukotriene LTA4 from arachidonic acid, which can then be converted to 
LTB4 [180].  Leukotrienes are important inflammatory mediators and LTB4 can then induce the 
adhesion and activation of leukocytes, ALOX5 is therefore mainly expressed in the different 
leukocytes [181].  In addition, ALOX5 might be capable of inducing cell cytotoxicity by oxidizing 
cellular membranes [182-183].  Leukotriene synthesis is reduced in the macrophages and 
peripheral mononuclear cells of HIV patients [184-186], as is supported by similar observation 
from the microarray analysis results on CD4+ T cells. 
 
Microarray data also revealed the significant elevation in ATP-binding cassette protein (ABCE1) 
levels in CD4+ T cells of HIV-1 infected patients as compared to normal.  Typically, ABCE1 is 
required for cellular survival, mRNA translation, and ribosome biogenesis.  It is the only ATP-
binding cassette enzyme that has an amino-terminal iron-sulfur cluster domain, thus necessitating 
the availability of iron for its functioning [143, 187].  During HIV-1 infection, cellular ABCE1 
interacts with viral Pr55 (Gag) and Vif to assist in capsid assembly.  While Vif is excluded from 
the mature viral particles, it is essential for viral infectivity.  It is therefore a late HIV-1 product, 
acting in the latter stages of the virus life cycle during viral assembly and/or maturation to 
enhance the infectivity of the progeny virions [188-189].   ABCE1 is known to function as an 
RNAse L inhibitor, suggesting that the viral association with ABCE1 is possibly to protect the 
viral RNA from degradation during viral assembly [188].  HIV-1 Gag polypeptides are 
synthesized in the cytoplasm of infected cells and then are trafficked to the plasma membrane.  
ABCE1 is then recruited to sites of assembling Gag at the membrane and the association 
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continues throughout capsid formation until the onset of viral maturation and its subsequent 
release [190]. 
 
More literature has been curated for HIV’s interactions with host proteins; however, similarities 
in microarray expression can insinuate comparable mechanisms utilized by hepatitis C.  However, 
the consequences associated with iron overload have been confirmed by much research in both 
HIV [143, 152-160] and hepatitis C [143, 149, 191-193].  In the latter,  not only does this 
overload correlate with progression of liver disease, fibrosis and carcinoma, it also results in a 
decreased response to antiviral therapy [149].  Nonetheless, despite all the efforts aimed at 
understanding the full role of iron in facilitating such viral infections, the mechanism and 
molecular explanation for the involvement of iron in these viral infection remains to be 
incomplete [143, 149]. 
 
5.6 Conclusion 
When HIV and hepatitis C infections hijack the host’s machinery, a complex interplay occurs 
between viral proteins and the host’s immune system and iron homeostasis.  Infecting viruses 
have to also posses the ability to enhance cellular metabolism in order to replicate their genome 
and proteins.  As these processes require iron, the virus has to ensure that the iron supply meets 
its proliferative demands.  Microarray analysis of the influence of HIV, hepatitis C and influenza 
A on iron binding proteins revealed that such proteins are major targets, whether direct or 
indirect, of viral infections.  In addition, while these iron binding proteins could comprise a 
general theme for viral infections, differences are observed between some of the major genes and 
proteins affected by persistent and non-persistent infections.  Some of these variations, in turn, 
are crucial for persistent viral survival and their abilities to avert the host’s immune system 
response enabling them to continue to reside within the host.
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Chapter 6: Concluding Remarks 
 
Complex diseases and infections are characterized by the multiplicity of genes and pathways that 
are altered within the patient or host to ensure disease or pathogenic persistence.  The advances in 
microarray technology has provided for a fast assay of the changes in gene regulation 
accompanied by the introduction of a multitude of perturbations including diseases, pathogens, 
drugs, gene knockouts and environmental modifications.  Such data can provide a quantitative 
profile of the expression of thousands of genes in a single experiment.  Biological significance 
can then be extended to genes of interest to identify the processes and pathways that succumb to 
the influence of these perturbations. 
 
DNA gene expression analysis has been widely used in the study of cancer [36-40], but has 
generated many inconsistencies across studies.  Apart from the lab-specific noise in the data that 
could interfere with the results, these disparities can arise because the number of samples used in 
studies does not meet the statistical requirements that support the thousands of genes that are 
assessed within the experiment.  However, as more data is deposited into publically accessible 
databases, researchers can acquire large amounts of data across hundreds of labs to analyze and to 
add statistical significance and confidence to their results.  Consequently, this research focused on 
an integrative method that could utilize data from different but similar platforms.  The research 
allows for data merger prior to analysis, contradictory to the common meta-analysis methods that 
combine results after datasets are analyzed separately.  Not only does the proposed method have 
the advantage of reducing experimental noise, it also takes advantage of the changes in sample 
distributions that have emerged in recent studies.  Therefore, this methodology is not restricted to 
datasets containing both control and test data, but can select for data from any experiment and 
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utilize the samples that are of interest, provided the experiment has been hybridized on one of the 
sister Affymetrix platforms; the HG-U133A, HG-U133A2, and HG-U133 Plus 2.0. 
 
The integrated method was based on the previously verified SAM statistical analysis approach as 
its performance is superior to that of other statistical methods, like the t-test and fold change [75].  
In addition, SAM allows for controlling the different parameters including p-values and fold 
change.  Testing the merged SAM approach on five cancer tissues: colon, kidney, liver, lung and 
pancreas, revealed its ability to capture large amounts of the experimental literature available on 
cancer that is independent of microarray usage.  Moreover, it has surpassed the capabilities of the 
inverse-variance meta-analysis technique applied to the same data.  This is supported by Nadon & 
Shoemaker [135] who noted that normalizing samples together adds robustness when compared 
to samples from datasets that have been normalized independently.  To understand the 
significance of the gene lists obtained from the independent tissue analyses, pathways enriched 
with these genes were identified.  The compliment and coagulation cascades and the ECM-
receptor interactions were among the common pathways associated with these cancers.  
Moreover, a combined normal/cancer analysis revealed the important aberrations that occur 
within the cell cycle, including the differential expression of cyclins A and B and cyclin-
dependent kinases (CDK1 and CDK4/6 complex), which are necessary for cell cycle progression.  
The merged SAM approach application in cancer was expanded to include an additional eight 
types of tissues to investigate the similarities in gene expression changes that occur across these 
tissues.  The cancer samples included for each tissue were not restricted to a specific grade or 
type, this allows for the identification of cancer type-independent features.  These common genes 
can prove to be essential drug targets for general cancer therapy and a few are already targeted by 
existing drugs while others are in the experimental phase. 
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The scope and utility of this research, however, is not limited to cancer investigations.  Therefore, 
its application was directed to the study of persistent and non-persistent viral infections.  In order 
for an infectious disease to replicate within the host’s cells, it must establish a connection with the 
host.  This crosstalk is essential for the different stages of the infection starting with the virus’ 
ability to bind to and fuse into a cell and ending with its escape from the cell to spread to other 
cells and hosts.  However, in between these two points the virus has to employ the cell’s 
machinery through further viral-host protein-protein interactions.  These interactions then allow 
the virus to replicate its genome, but it also triggers other pathways such as immune response and 
apoptosis, especially for non-persistent infections.  Persistent viruses, on the other hand, have 
developed ways to escape the immune system and ensure their continued existence within the 
host. 
 
Much of these biological processes and pathways, varying from DNA replication to immune 
response, involve proteins that bind iron.  DNA microarray data was therefore used to identify 
those iron binding proteins that exhibited altered expression at the transcript level due to viral 
infections.  This is especially important since iron overload occurring in patients with persistent 
viral infections is believed to correlate with disease progression and decreased survival in 
hepatitis C and HIV, respectively.  Merged microarray results confirmed some of the known 
effects HIV exerts on the host’s proteins it directly interacts with and similar results were 
observed under hepatitis C infection, suggesting comparable hijacking approaches.  However, 
comparison of results with influenza A, a non-persistent infection chosen as a control, revealed 
that iron-dependent proteins are the target of viruses in general, as these proteins are mainly 
involved in metabolic processes.  Nonetheless, some of the genes altered exclusively in persistent 
viruses could be related to viral lengthened survival and escaping the host’s immune response. 
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The shortcomings however arise from the disparities in focus on the diseases studied.  The 
majority of the currently available gene expression experiments are dedicated towards the study 
of cancer as opposed to infectious diseases and other pathologies.  For example, thousands of 
microarray samples exist containing data on a wide range of malignancies, however, only tens of 
samples exist for HIV infections.  Even within cancer itself, a great effort has been devoted to 
certain malignancies such as breast cancer, where thousands of data points are available for each 
gene, compared to adrenal, pancreatic and cervical cancers that have far fewer samples.  Another 
limitation is also imposed by the platform restrictions required by the merged SAM.  However, 
Affymetrix has been shown to result in better accuracy than other platforms [194].  Moreover, 
integrating data from different technologies (Affymetrix/cDNA) is unreliable [133-134]. 
 
The molecular pathways affected by cancer also involve noncoding genes; these include the 
noncoding class of small RNAs referred to as microRNA (miRNA).  While these miRNAs are not 
translated into proteins, they are instead involved in the regulation of mRNA translation [195-
196].  Functionally, these miRNAs can reduce the amount of proteins produced by their target 
transcripts, and thus they are essential for several biological pathways including cell proliferation 
[195].  Cancer can affect the expression of miRNA through mutations, polymorphisms, 
chromosomal abnormalities and epigenetic changes.  These in turn result in defects in the miRNA 
biogenesis machinery.  Such changes in turn can promote oncogenesis by altering the gene 
expression of oncogenes and tumor suppressor genes [196].  Future work will add to the obtained 
cancer knowledge by exploiting changes at the miRNA level associated with the different 
malignancies.  Not only are these abnormal miRNA profiles essential for cancer diagnosis, they 
can also play a dual role in cancer therapy.  Since the miRNA profiles are conserved from the 
primary tumor to the metastatic cancer, cancer therapy can utilize miRNA as therapeutics and 
also target them through anti-miRNA therapy [196].   
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Appendix A: General cancer SAM genes 
 
 
Table A1  - Annotation of General Cancer SAM Genes: List of genes that appeared to be 
differentially expressed in at least 70% of the iterations when selecting 10 random samples from 
each tissue for general normal to cancer tissue comparisons 
Entrez ID Frequency (%) Gene Symbol Gene Name 
125 100 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide 
699 100 BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast) 
701 100 BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog 
beta (yeast) 
705 100 BYSL bystin-like 
983 100 CDC2 cell division cycle 2, G1 to S and G2 to M 
990 100 CDC6 cell division cycle 6 homolog (S. cerevisiae) 
991 100 CDC20 cell division cycle 20 homolog (S. cerevisiae) 
1019 100 CDK4 cyclin-dependent kinase 4 
1058 100 CENPA centromere protein A 
1063 100 CENPF centromere protein F, 350/400ka (mitosin) 
1111 100 CHEK1 CHK1 checkpoint homolog (S. pombe) 
1164 100 CKS2 CDC28 protein kinase regulatory subunit 2 
1282 100 COL4A1 collagen, type IV, alpha 1 
1300 100 COL10A1 collagen, type X, alpha 1(Schmid metaphyseal 
chondrodysplasia) 
1736 100 DKC1 dyskeratosis congenita 1, dyskerin 
1786 100 DNMT1 DNA (cytosine-5-)-methyltransferase 1 
2146 100 EZH2 enhancer of zeste homolog 2 (Drosophila) 
2237 100 FEN1 flap structure-specific endonuclease 1 
2305 100 FOXM1 forkhead box M1 
2537 100 IFI6 interferon, alpha-inducible protein 6 
3161 100 HMMR hyaluronan-mediated motility receptor (RHAMM) 
4171 100 MCM2 minichromosome maintenance complex component 2 
4172 100 MCM3 minichromosome maintenance complex component 3 
4174 100 MCM5 minichromosome maintenance complex component 5 
4176 100 MCM7 minichromosome maintenance complex component 7 
4192 100 MDK midkine (neurite growth-promoting factor 2) 
4306 100 NR3C2 nuclear receptor subfamily 3, group C, member 2 
4495 100 MT1G metallothionein 1G 
4499 100 MT1M metallothionein 1M 
4830 100 NME1 non-metastatic cells 1, protein (NM23A) expressed in 
5050 100 PAFAH1B3 platelet-activating factor acetylhydrolase, isoform Ib, 
gamma subunit 29kDa 
5111 100 PCNA proliferating cell nuclear antigen 
5984 100 RFC4 replication factor C (activator 1) 4, 37kDa 
6241 100 RRM2 ribonucleotide reductase M2 polypeptide 
6491 100 STIL SCL/TAL1 interrupting locus 
6696 100 SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1) 
6790 100 AURKA aurora kinase A 
7123 100 CLEC3B C-type lectin domain family 3, member B 
7153 100 TOP2A topoisomerase (DNA) II alpha 170kDa 
7203 100 CCT3 chaperonin containing TCP1, subunit 3 (gamma) 
7272 100 TTK TTK protein kinase 
8317 100 CDC7 cell division cycle 7 homolog (S. cerevisiae) 
8318 100 CDC45L CDC45 cell division cycle 45-like (S. cerevisiae) 
8480 100 RAE1 RAE1 RNA export 1 homolog (S. pombe) 
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Table A1 (continued) 
Entrez ID Frequency (%) Gene Symbol Gene Name 
8607 100 RUVBL1 RuvB-like 1 (E. coli) 
8914 100 TIMELESS timeless homolog (Drosophila) 
8985 100 PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
9055 100 PRC1 protein regulator of cytokinesis 1 
9133 100 CCNB2 cyclin B2 
9212 100 AURKB aurora kinase B 
9232 100 PTTG1 pituitary tumor-transforming 1 
9319 100 TRIP13 thyroid hormone receptor interactor 13 
9636 100 ISG15 ISG15 ubiquitin-like modifier 
9735 100 KNTC1 kinetochore associated 1 
9768 100 KIAA0101 KIAA0101 
9787 100 DLG7 discs, large homolog 7 (Drosophila) 
9833 100 MELK maternal embryonic leucine zipper kinase 
9837 100 GINS1 GINS complex subunit 1 (Psf1 homolog) 
9918 100 NCAPD2 non-SMC condensin I complex, subunit D2 
9928 100 KIF14 kinesin family member 14 
10051 100 SMC4 structural maintenance of chromosomes 4 
10112 100 KIF20A kinesin family member 20A 
10351 100 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 
10460 100 TACC3 transforming, acidic coiled-coil containing protein 3 
10535 100 RNASEH2A ribonuclease H2, subunit A 
10635 100 RAD51AP1 RAD51 associated protein 1 
10643 100 IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 
11004 100 KIF2C kinesin family member 2C 
11065 100 UBE2C ubiquitin-conjugating enzyme E2C 
11130 100 ZWINT ZW10 interactor 
22827 100 PUF60 poly-U binding splicing factor 60KDa 
22974 100 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 
23636 100 NUP62 nucleoporin 62kDa 
24137 100 KIF4A kinesin family member 4A 
25788 100 RAD54B RAD54 homolog B (S. cerevisiae) 
25928 100 SOSTDC1 sclerostin domain containing 1 
26586 100 CKAP2 cytoskeleton associated protein 2 
29127 100 RACGAP1 Rac GTPase activating protein 1 
51203 100 NUSAP1 nucleolar and spindle associated protein 1 
51659 100 GINS2 GINS complex subunit 2 (Psf2 homolog) 
54478 100 FAM64A family with sequence similarity 64, member A 
54892 100 NCAPG2 non-SMC condensin II complex, subunit G2 
55165 100 CEP55 centrosomal protein 55kDa 
55257 100 C20orf20 chromosome 20 open reading frame 20 
55732 100 C1orf112 chromosome 1 open reading frame 112 
55872 100 PBK PDZ binding kinase 
56992 100 KIF15 kinesin family member 15 
57405 100 SPC25 SPC25, NDC80 kinetochore complex component, homolog 
(S. cerevisiae) 
64151 100 NCAPG non-SMC condensin I complex, subunit G 
79005 100 SCNM1 sodium channel modifier 1 
79019 100 CENPM centromere protein M 
79581 100 GPR172A G protein-coupled receptor 172A 
79762 100 C1orf115 chromosome 1 open reading frame 115 
79801 100 SHCBP1 SHC SH2-domain binding protein 1 
84823 100 LMNB2 lamin B2 
142 99 PARP1 poly (ADP-ribose) polymerase family, member 1 
332 99 BIRC5 baculoviral IAP repeat-containing 5 (survivin) 
443 99 ASPA aspartoacylase (Canavan disease) 
471 99 ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
890 99 CCNA2 cyclin A2 
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Table A1 (continued) 
Entrez ID Frequency (%) Gene Symbol Gene Name 
790 99 CAD carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase 
871 99 SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) 
994 99 CDC25B cell division cycle 25 homolog B (S. pombe) 
1062 99 CENPE centromere protein E, 312kDa 
2949 99 GSTM5 glutathione S-transferase M5 
4288 99 MKI67 antigen identified by monoclonal antibody Ki-67 
4886 99 NPY1R neuropeptide Y receptor Y1 
9493 99 KIF23 kinesin family member 23 
9569 99 GTF2IRD1 GTF2I repeat domain containing 1 
9631 99 NUP155 nucleoporin 155kDa 
10894 99 LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 
11339 99 OIP5 Opa interacting protein 5 
25840 99 METTL7A methyltransferase like 7A 
29107 99 NXT1 NTF2-like export factor 1 
79888 99 AYTL2 acyltransferase like 2 
84981 99 MGC14376 hypothetical protein MGC14376 
898 98 CCNE1 cyclin E1 
1503 98 CTPS CTP synthase 
3627 98 CXCL10 chemokine (C-X-C motif) ligand 10 
4128 98 MAOA monoamine oxidase A 
4318 98 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
4940 98 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 
6659 98 SOX4 SRY (sex determining region Y)-box 4 
6772 98 STAT1 signal transducer and activator of transcription 1, 91kDa 
9123 98 SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
10212 98 DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 
23492 98 CBX7 chromobox homolog 7 
55355 98 URLC9 up-regulated in lung cancer 9 
1434 97 CSE1L CSE1 chromosome segregation 1-like (yeast) 
5708 97 PSMD2 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 2 
22880 97 MORC2 MORC family CW-type zinc finger 2 
23594 97 ORC6L origin recognition complex, subunit 6 like (yeast) 
51373 97 MRPS17 mitochondrial ribosomal protein S17 
1776 96 DNASE1L3 deoxyribonuclease I-like 3 
4320 96 MMP11 matrix metallopeptidase 11 (stromelysin 3) 
8662 96 EIF3B eukaryotic translation initiation factor 3, subunit B 
10095 96 ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 
10403 96 NDC80 NDC80 homolog, kinetochore complex component (S. 
cerevisiae) 
10797 96 MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate cyclohydrolase 
51660 96 BRP44L brain protein 44-like 
57122 96 NUP107 nucleoporin 107kDa 
80308 96 FLAD1 FAD1 flavin adenine dinucleotide synthetase homolog (S. 
cerevisiae) 
1469 95 CST1 cystatin SN 
2335 95 FN1 fibronectin 1 
3624 95 INHBA inhibin, beta A 
5433 95 POLR2D polymerase (RNA) II (DNA directed) polypeptide D 
23213 95 SULF1 sulfatase 1 
79075 95 DCC1 defective in sister chromatid cohesion homolog 1 (S. 
cerevisiae) 
103 94 ADAR adenosine deaminase, RNA-specific 
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Table A1 (continued) 
Entrez ID Frequency (%) Gene Symbol Gene Name 
2191 94 FAP fibroblast activation protein, alpha 
5436 94 POLR2G polymerase (RNA) II (DNA directed) polypeptide G 
7004 94 TEAD4 TEA domain family member 4 
9688 94 NUP93 nucleoporin 93kDa 
54512 94 EXOSC4 exosome component 4 
81930 94 KIF18A kinesin family member 18A 
3832 93 KIF11 kinesin family member 11 
5202 93 PFDN2 prefoldin subunit 2 
6472 93 SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) 
6944 93 VPS72 vacuolar protein sorting 72 homolog (S. cerevisiae) 
7371 93 UCK2 uridine-cytidine kinase 2 
9314 93 KLF4 Kruppel-like factor 4 (gut) 
10606 93 PAICS phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide 
synthetase 
54517 93 PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) 
79980 93 DSN1 DSN1, MIND kinetochore complex component, homolog 
(S. cerevisiae) 
4237 92 MFAP2 microfibrillar-associated protein 2 
6626 92 SNRPA small nuclear ribonucleoprotein polypeptide A 
29901 92 SAC3D1 SAC3 domain containing 1 
762 91 CA4 carbonic anhydrase IV 
5348 91 FXYD1 FXYD domain containing ion transport regulator 1 
(phospholemman) 
23306 91 TMEM194 transmembrane protein 194 
54981 91 C9orf95 chromosome 9 open reading frame 95 
1890 90 ECGF1 endothelial cell growth factor 1 (platelet-derived) 
4017 90 LOXL2 lysyl oxidase-like 2 
4173 90 MCM4 minichromosome maintenance complex component 4 
4521 90 NUDT1 nudix (nucleoside diphosphate linked moiety X)-type motif 
1 
4751 90 NEK2 NIMA (never in mitosis gene a)-related kinase 2 
7704 90 ZBTB16 zinc finger and BTB domain containing 16 
9238 90 TBRG4 transforming growth factor beta regulator 4 
7102 89 TSPAN7 tetraspanin 7 
7965 89 JTV1 JTV1 gene 
23397 89 NCAPH non-SMC condensin I complex, subunit H 
5690 88 PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 
11335 88 CBX3 chromobox homolog 3 (HP1 gamma homolog, Drosophila) 
4794 87 NFKBIE nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, epsilon 
10248 87 POP7 processing of precursor 7, ribonuclease P/MRP subunit (S. 
cerevisiae) 
10376 87 TUBA1B tubulin, alpha 1b 
51512 87 GTSE1 G-2 and S-phase expressed 1 
84722 87 PSRC1 proline/serine-rich coiled-coil 1 
5993 86 RFX5 regulatory factor X, 5 (influences HLA class II expression) 
10974 86 C10orf116 chromosome 10 open reading frame 116 
54908 86 CCDC99 coiled-coil domain containing 99 
55226 86 NAT10 N-acetyltransferase 10 
2104 85 ESRRG estrogen-related receptor gamma 
2535 85 FZD2 frizzled homolog 2 (Drosophila) 
4001 85 LMNB1 lamin B1 
5138 85 PDE2A phosphodiesterase 2A, cGMP-stimulated 
6358 85 CCL14 chemokine (C-C motif) ligand 14 
6628 85 SNRPB small nuclear ribonucleoprotein polypeptides B and B1 
7045 85 TGFBI transforming growth factor, beta-induced, 68kDa 
7049 85 TGFBR3 transforming growth factor, beta receptor III 
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Table A1 (continued) 
Entrez ID Frequency (%) Gene Symbol Gene Name 
25903 85 OLFML2B olfactomedin-like 2B 
79866 85 C13orf34 chromosome 13 open reading frame 34 
5427 84 POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) 
5531 84 PPP4C protein phosphatase 4 (formerly X), catalytic subunit 
5725 84 PTBP1 polypyrimidine tract binding protein 1 
6185 84 RPN2 ribophorin II 
8228 84 PNPLA4 patatin-like phospholipase domain containing 4 
55131 84 RBM28 RNA binding motif protein 28 
1408 83 CRY2 cryptochrome 2 (photolyase-like) 
1462 83 VCAN versican 
3925 83 STMN1 stathmin 1/oncoprotein 18 
5033 83 P4HA1 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 
4-hydroxylase), alpha polypeptide I 
9134 83 CCNE2 cyclin E2 
9413 83 C9orf61 chromosome 9 open reading frame 61 
10926 83 DBF4 DBF4 homolog (S. cerevisiae) 
51092 83 SIDT2 SID1 transmembrane family, member 2 
55143 83 CDCA8 cell division cycle associated 8 
687 82 KLF9 Kruppel-like factor 9 
79134 82 TMEM185B transmembrane protein 185B 
3978 81 LIG1 ligase I, DNA, ATP-dependent 
64754 81 SMYD3 SET and MYND domain containing 3 
7852 80 CXCR4 chemokine (C-X-C motif) receptor 4 
80157 80 FLJ21511 hypothetical protein FLJ21511 
3014 79 H2AFX H2A histone family, member X 
55038 79 CDCA4 cell division cycle associated 4 
217 78 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 
1675 78 CFD complement factor D (adipsin) 
4494 78 MT1F metallothionein 1F 
7329 78 UBE2I ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 
10537 78 UBD ubiquitin D 
25896 78 INTS7 integrator complex subunit 7 
1875 77 E2F5 E2F transcription factor 5, p130-binding 
3576 77 IL8 interleukin 8 
5412 77 UBL3 ubiquitin-like 3 
7076 77 TIMP1 TIMP metallopeptidase inhibitor 1 
55723 77 ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 
64943 77 NT5DC2 5'-nucleotidase domain containing 2 
1017 76 CDK2 cyclin-dependent kinase 2 
2819 76 GPD1 glycerol-3-phosphate dehydrogenase 1 (soluble) 
3248 76 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 
9452 76 ITM2A integral membrane protein 2A 
288 75 ANK3 ankyrin 3, node of Ranvier (ankyrin G) 
813 75 CALU calumenin 
2189 75 FANCG Fanconi anemia, complementation group G 
5328 75 PLAU plasminogen activator, urokinase 
5351 75 PLOD1 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 
5982 75 RFC2 replication factor C (activator 1) 2, 40kDa 
6338 75 SCNN1B sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) 
7433 75 VIPR1 vasoactive intestinal peptide receptor 1 
9079 75 LDB2 LIM domain binding 2 
865 74 CBFB core-binding factor, beta subunit 
2960 74 GTF2E1 general transcription factor IIE, polypeptide 1, alpha 56kDa 
4501 74 MT1X metallothionein 1X 
6895 74 TARBP2 TAR (HIV-1) RNA binding protein 2 
27286 74 SRPX2 sushi-repeat-containing protein, X-linked 2 
56920 74 SEMA3G sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3G 
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Table A1 (continued) 
Entrez ID Frequency (%) Gene Symbol Gene Name 
6414 73 SEPP1 selenoprotein P, plasma, 1 
2690 72 GHR growth hormone receptor 
3068 72 HDGF hepatoma-derived growth factor (high-mobility group 
protein 1-like) 
5987 72 TRIM27 tripartite motif-containing 27 
9603 72 NFE2L3 nuclear factor (erythroid-derived 2)-like 3 
29980 72 DONSON downstream neighbor of SON 
79833 72 GEMIN6 gem (nuclear organelle) associated protein 6 
7754 71 ZNF204 zinc finger protein 204 
633 70 BGN biglycan 
3131 70 HLF hepatic leukemia factor 
5437 70 POLR2H polymerase (RNA) II (DNA directed) polypeptide H 
9168 70 TMSB10 thymosin, beta 10 
10964 70 IFI44L interferon-induced protein 44-like 
63924 70 CIDEC cell death-inducing DFFA-like effector c 
93594 70 WDR67 WD repeat domain 67 
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